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Zusammenfassung: 
 
Das 29 kDa Metalloprotein humane Carbonische Anhydrase (HCAII) katalysiert die 
Reaktion H2O + CO2 ↔ HCO3- + H+. In menschlichen Erythrozyten bindet sie an den 
humane Anionen Transporter 1 (HAE1), der HCO3-  gegen Cl- Ionen durch die 
Zellmembrane der roten Blutkörperchen schleußt, und bildet so ein Metabolon. Ein 
Metabolon ist ein Komplex aus schwach interagierenden Bindungspartnern. Dadurch 
können Metabolite ohne Verlust von einer „aktive site“ zur nächsten geleitet werden, 
wodurch der Prozeß an Effizienz gewinnt. Das HCAII – HAE1 Metabolon wurde in 
verschiedenen Geweben nachgewiesen, wobei es auch außerhalb respiratorischer 
Prozesse Schlüsselfunktionen in der Sekretion von Chlorid oder Hydrogencarbonat 
Ionen einnimmt.  
HCAII interagiert auch mit anderen Mitgliedern der drei HCO3-  - Transporter 
Familien. Diese Tatsache unterstreicht die Wichtigkeit dieser HCO3-  - Transport 
Metabolons in verschiedenen Geweben.  
Vorhergehende Studien haben bewiesen, dass HCAII durch seine N- terminale helix 
mit der C- terminalen cytoplasmischen region von HAE1 interagiert. Die C- terminale 
Sequence L886DADD des HAE1 spielt dabei eine wichtige Rolle. Ob andere Motive 
für die Komplexbildung wichtig sind, war unklar. Außerdem konnte die 
Bindungsstelle auf HCAII noch nicht bestimmt werden.  
Durch NMR- Messung konnte nachgewiesen warden, dass die Aminosäuren E882 
und E899 zusätzlich zur Sequence L886DADD auf dem C- Terminus von HAE1 für 
die Komplexbildung mit HCAII wichtig sind. Außerdem kann aufgrund von NMR 
Titrations- Experimenten angenommen werden, dass die Bindungstelle des C- 
terminus von HAE1 nahe dem Zugang zur „active site“ von HCAII liegt.  
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Abstract: 
 
The 29 kDa metalloprotein human carbonic anhydrase II (HCAII) catalyzes the 
reaction H2O + CO2 ↔ HCO3- + H+. In erythrocytes it binds to the HCO3- transporter 
human anion exchanger 1 (HAE1) forming a metabolon. A metabolon is a complex of 
weakly interacting binding partners passing on very efficiently substrates from one 
active site to another and thereby facilitating the process dramatically. This metabolon 
formed by HCAII and HAE1 was detected in a variety of tissues involved in Cl- and 
/or HCO3- secretion and respiratory processes. Moreover HCAII was reported to 
interact with members of all HCO3- transporter families. Therefore the interaction site 
of HCAII and HAE1 is in the focus of studies concerning HCO3- transporter 
metabolons. 
Based on previous studies the C-terminal cytoplasmic region of HAE1 (HAE1ct) 
interacts with the basic N- terminal helix of HCAII by the hydrophobic - acidic motif 
L886DADD. If other motifs on HAE1 ct are also involved was unclear. Moreover the 
binding site of HAE1ct on HCAII was not known. However it was discovered that the 
truncation 17 amino acids at the N- terminus is connected with disruption of the 
complex. 
Based on NMR titration studies we discovered that E882 (upstream the acidic motif) 
and E899 (downstream the acidic motif) on HAE1 C-terminal region are also 
involved in complex formation with HCAII and even more essential. Additionally the 
binding site of HAE1 C-terminal region to HCAII was mapped close the entry to its 
active site. 
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1. Introduction 
 
1.1 The capno metabolon; an example for the HCO3- 
transport metabolon 
1.1.1 Human carbonic anhydrase I and II (HCAI and HCAII) in red 
blood cells 
 
16 different isoforms (cytosoplasmic and membrane- bound) of carbonic anhydrase 
were found in mammalian tissue. We focus on the isoforms I and II which are 
predominantly expressed in erythrocytes (Sly and Hu 1995). 
 
Patients lacking isoform I do not have any serious symptoms (Kendall and Tashian 
1977) while the lack of HCAII is not lethal but causes autosomal recessive 
osteopetrosis with renal tubular acidosis and cerebral calcification(Sly, Whyte et al. 
1985).  
This is surprising because HCAI is 6 times more abundant in erythrocytes (130 µM) 
than CAII (20 µM) and both catalyze the same reaction (Vince and Reithmeier 2000): 
H2O+ CO2 ↔ HCO3- + H+ 
They also share 60% sequence identity and have a similar 3D structure (Liljas, 
Kannan et al. 1972; Kannan, Notstrand et al. 1975). 
However the turnover rate of isoform II is 7 times higher than that of isoform I 
(Reithmeier 2001). Moreover HCAI is highly inhibited by the concentration of Cl- in 
red blood cells (Reithmeier 2001). 
Why is HCAII therefore so important in red blood cells at difference to HCAI ? It is 
part of a metabolon. 
HCAII can interact with HCO3- while HCAI as unable to do so.  
 
1.1.2 The Capno Metabolon 
 
It was proved that HCAII can interact with human anion exchanger 1 (HAE1; Band 
3). This anion antiporter transports HCO3- against Cl-- ions. The interaction between 
HCAII and this transporter allows the transport of substrate HCO3- from and to 
HCAII without any loss, which is dramatically enhancing the efficiency of the 
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process. Human carbonic anhydrase II is located close to the membrane by this 
interaction,  
 
The interaction of HCAII with HAEI localizes HCAII close to the membrane where 
high pools of CO2 are found. The diffusion of CO2 through the unstirred water on the 
cell membrane would be rather difficult (Reithmeier 2001).  
Counter current studies also suggested that HCAII can also bind to hemoglobin 
(Backman 1981). This means that the free H+ produced in the interconversion of H2O 
and CO2 could be passed directly to hemoglobin and thereby decrease its affinity for 
O2. Hemoglobin seems to have a role in enhancing the catalytic activity of HCAII by 
exchange of the H2O produced in the interconversion of HCO3-(Silverman, Backman 
et al. 1979). 
Aquaporin 1 (AQP1) could be involved in this complex and therefore directly deliver 
H2O to HCAII (Reithmeier 2001).  
 
 
Figure 1: The Capno Metabolon (Reithmeier 2001) 
 
In tissue, CO2 diffuses through the lipid bilayer while H2O is passed through APQ1 to 
the inside of the cell. These substrates are converted by HCAII to HCO3- which is 
transported outside the cell by HAE1 and H+ which binds to hemoglobin. This 
binding induces a conformational change in hemoglobin leading to a decrease of 
affinity for O2. In the lungs HCO3- is reconverted to H2O and CO2 which diffuses out 
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of the red blood cells and is expired inducing a conformation change in hemoglobin 
increasing its affinity for O2 (Reithmeier 2001) (Figure 1). 
 
This series of interactions that channel substrates and products of carbonic anhydrase 
defines the capno metabolon. Capno is a greek word meaning smoke or CO2. A 
metabolon is a complex of weakly interacting binding partners which allow substrates 
to be transported from one active site to the next and are therefore responsible for the 
fine tuning of the whole process.  
In the following we shall take a closer look at the interaction partners HCAII and 
HAE1. 
1.1.3 HCAII 
 
It is a 29 kDa protein with overall dimensions of 55×42×41 Å (Reithmeier 2001). In 
similarity to HCAI it has a Zn- Ion buried deep in its active site coordinated by 3 
histidine residues and one hydroxide ion. However, unlike in HCAI, the 20 N-
terminal residues fold to an α- helix independently from the rest of the protein. 
Moreover, this region contains histidine residiues which cannot be found in the 
sequence of HCAI (Reithmeier 2001).  
 
N- terminally truncated versions of HCAII partly lose their catalytic activity enzyme 
in complex with HAE1, indicating that this region is involved in binding to HAE1, 
which in turn localizes HCAII close to the membrane (Sterling, Reithmeier et al. 
2001). 
HCAII is widely distributed in tissue. In osteocasts, kidney tubules and parietal cells it 
is responsible for acid secretion while in choroid plexus, pancreatic duct cells and 
salivary gland acinar cells it promotes  HCO3-  secretion (Reithmeier 2001). In red 
blood cells it has an important role in blood buffering and is essential for respiratory 
processes. This important role in a variety of processes the severe damage of its 
absence can be explained.  
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1.1.4 Human anion exchanger (HAE1) 
 
Human anion exchanger, also termed human band 3, is a 911- amino acid 
glycoprotein. Its C- terminal region (55 kDa) spans the cell membrane 12 – 14 times 
and ends as a 33 amino acid peptide in the cytoplasm. The N- terminus forms a 
cytoplasmic domain (43 kDa) which binds glycolytic proteins and anchors HAE1 to 
the membrane cytoskeleton (Zhang, Kiyatkin et al. 2000).  
 
The anion exchanges (AE) family comprises additional two members AE2 and AE3. 
AE1 is abundantly expressed in erythrocytes and a truncated version is also present in 
the kidney and the heart (Sterling, Alvarez et al. 2002). AE2 is almost ubiquitous 
while AE3 is expressed in the heart, brain and retina (Sterling, Alvarez et al. 2002). 
That means that AE family can be found throughout the body.  
 
1.1.5 Interaction between HCAII and HAE1 
 
The interaction between HCAII and HAE1 was proved by immunofluorescence, co-
immunoprecipitation and micro- titer assays (Vince and Reithmeier 1998). 
HAE1 C- terminal region blocked the interaction of GST- ct with an affinity of 100 
µM. The micro titer plate assays indicated a binding constante of 100 nM. However 
an interaction in the micromolar range seems to be more probable (Reithmeier 2001).  
It was also shown that inhibition of HCAII by azetolamide decreased the activity of 
HAE1 to approximately 70%. The loss of interaction by truncation of N-terminal 
region or mutations in this region had the same effects (Sterling, Reithmeier et al. 
2001).  
It was also found out that the 33 C- terminal amino acids of HAE1 are sufficient to 
interact with HCAII (Vince and Reithmeier 1998). 
 
1.1.5.1 The acidic-basic motif of the interaction between HCAII and HAE1 
 
The interaction is dramatically dependent on pH and ionic strength. The binding rate 
was rather slow (t1/2= 12h) at physiological pH and ionic strength (50 mM Tris pH7.5 
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100 mM NaCl). By lowering the pH and ionic strength, the time to reach saturation of 
binding was decreased (Vince and Reithmeier 1998). It is therefore rather probable 
that the interaction is electrostatic, based on acidic and/or basic motifs.  
The N- terminal helix of HCAII contains basic amino acids and 5 histidine residues, 
which are not present in isoform I. Truncation of this region results in loss of binding 
while the enzymatic activity is still preserved (Vince, Carlsson et al. 2000). In contrast 
the 33 amino acid C-terminal region of HAE1 is highly acidic.  
 
In order to map the binding site different N-terminally truncated versions of HCAII 
were investigated if they can still bind the 33 amino acid C-terminal region of 
HAE1(Vince, Carlsson et al. 2000). 
 
 
Figure 2: Effect of N- terminal truncations of HCAII on the binding with the c- terminal 33 
amino acid peptide of HAE1 (Vince, Carlsson et al. 2000) 
 
The truncation of 17 or 24 N- terminal amino acids lead to a loss of binding while the 
truncation of the first 5 residues resulted in 20% decrease in binding (Figure 2). 
Furthermore, the role of the histidine residues in this region was tested. They are 
highly conserved throughout all organisms. 
 
Combinations of mutations were done but only the mutation of all positively charged 
residues ( 5 histidine residues and lysine 9) resulted in a complete loss of binding. 
That indicates that these histidine residues are important for structure or that they 
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form an “electrostatic platform” for the interaction between HAE1 and HCAII, 
facilitating therefore exchange of HCO3- with HAE1(Vince, Carlsson et al. 2000). 
 
The C-terminal region of HAE1 contains 3 patches with high content of acidic amino 
acid residues. Again, truncation experiments were performed, showing that the acidic 
patch D887ADD was essential for binding to HCAII. By mutations it was found out 
that the sequence of these four amino acids can be changed but it has to include at 
least two acidic amino acids (Vince and Reithmeier 2000).  
It has additionally been shown that HAE2 can as well bind to HCAII. Here the 
sequence D887ANE, which again contains two acidic amino acids, seems to be 
important for binding (Vince and Reithmeier 2000).  
L886 is conserved in HAE1 and HAE2, therefore its role was investigated by the 
mutation to alanine. The interaction was completely loss indicatating that L886 has an 
important role in interaction.  
 
 
Figure 3: Comparison  of primary sequences of HAE1 and HAE2 (Vince and Reithmeier 2000) 
Consensus sequence (orange) other acidic motifs (green) 
 
L886DADD was proposed to be a consensus sequence for interaction of HAE1 with 
HCAII while a similar sequence is found in HAE2 (Figure 3). This sequence motif 
can also be found in the primary sequence of Aquaporin 1 (AQP1) (Vince and 
Reithmeier 2000), suggesting a similar binding mode.  
 
Putative carbonic anhydrase binding sites on HAE1 therefore consist of a 
hydrophobic amino acid followed by four amino acid residues, of which at least two 
have to be acidic. This motif was also found in HAE2 (intra- and extracellular), 
aquaporin 1, SLC26A6 (anion transporter) and others. This proposes that the 
bicarbonate transport metabolon is essential in different tissues and for different 
purposes. Hereafter we shall take a look at proposed components in these metabolons. 
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1.2 Components of HCO3- transporter metabolons 
throughout the body 
1.2.1 HCO3- exchangers 
 
There are three groups of exchangers which transport HCO3- through the membrane: 
1. SLC4a Cl-/HCO3- exchangers (AE family) 
2. SLC4a sodium coupled transporters  
3. SLC26a family 
 
The members of the SLC4A anion exchanger (AE) family and the SLC26A anion 
transport family mediate anion exchange at the plasma membrane of mammalian cells 
while the SLC26a family is involved in channeling different anionic substrates for 
example sulfate, formate, oxalate, nitrate, iodide etc (Esbaugh and Tufts 2006). 
Within all these groups there are now examples (AE2, NHE1, kNBC1, NBC3, DRA) 
for interaction with carbonic anhydrases (Alvarez, Vilas et al. 2005), employing a 
variety of possible interaction sites apart the interaction motif of HAE1. For kNBC1 it 
is believed that two acidic motifs are involved in the binding (Pushkin, Abuladze et al. 
2004). However, NHE1 seems to interact with HCAII via S796 and D797, 
constituting a novel binding motif (Li, Liu et al. 2006). 
The metabolon of SLC26A6 with HCAII is disrupted by phosporylation near the 
carbonic anhydrase binding site. This could be a universal mechanism of metabolon 
regulation (Alvarez, Vilas et al. 2005) as also the binding of kNBC1 to HCAII is 
altered by phosporylation (Gross, Pushkin et al. 2002). 
 
1.2.2 Carbonic anhydrases (CA) 
 
Carbonic anhydrases are metalloenzymes carrying a Zn- ion in their active site.  
The dominant secondary structure motives are β-sheets (Figure 4). 
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                                 Figure 4: Structure of human carbonic anhydrase II 
 
All of them are catalyzing the de- and rehydration of CO2 (Figure 5).  
CO2 undergoes a nucleophilic attack by Zn- bound hydroxide. HCO3- is directly 
formed bypassing the slow reaction over carbonic acid and its dissociation. HCO3- on 
the Zn- ion is replaced by a water molecule. The Zn- binding hydroxide is regenerated 
by remove of a proton from the water molecule by the proton shuttling mechanism. 
The catalytic function of CA is based on four main structural components.  
 
1. Zn- binding site 
2. substrate association pocket 
3. threonine 199 loop 
4. proton shuttling mechanism 
 
The Zn- ion is coordinated by three histidine residues (His 94; His 96; His 119) and a 
hydroxide molecule. Each histidine residue has an associated ligand (Gln 92; Asn 244 
and Glu 117) which stabilizes these residues by a hydrogen bond.  
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Figure 5: Active site of HCAII 
 
The substrate binding pocket consists of six non- polar amino acid residues which 
channel CO2 to the Zn- ion. 
The main function of the Thr199 loop is to keep the Zn- bound hydroxyl group in the 
right orientation for catalysis. This is accomplished by the formation of a hydrogen 
bonding network.  
The proton produced by the reaction is moved through a shuttle chain consisting of 
three H2O molecules (Figure) before it guided by the proton shuttling mechanism. In 
HCAII the shuttling is highly dependent on His64, which mutation results in 
dramatical decrease of catalytic function.  
 
16 isoforms of carbonic anhydrases are known. The family comprises cytoplasmic 
(CAI, II, II, V, VII, and XIII), membrane- bound (VI, IX, XII, XIV and XV) and CA- 
related proteins which have lost their catalytic function(Esbaugh and Tufts 2006).  
 
1.2.2.1 Cytoplasmic CA 
 
Out of six CA isoforms two are high turnover (CAII and CAVII), three are low 
turnover (CAI, V and XIII) and CAII has an extreme low turnover rate. This is due to 
structural modifications of the proton shuttling mechanism or reduction of the active 
site cavity (isoform I).  
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Phylogenetic analysis revealed that CAV and VII are the most ancestral enzymes and 
seem to have limited roles in vertebrates(Esbaugh and Tufts 2006).  
CAV is expressed in liver and muscle mitrochondria while CAII and CAI are widely 
distributed in all tissues (Esbaugh and Tufts 2006).  
1.2.2.2 Membrane bound CA 
 
Among the membrane bound CAs, three (IX, XII and XIV) have transmembrane 
domains while the two others (IV and XV) are bound to the membrane via glycosyl-
phospatidyl-inositol (GPI) - anchors. Nearly all of them (with exception of CAXV) 
have a high turnover. The reason for this is a disulfide bridge between Cys23 and 
Cys203 residues, which stabilizes the Thr199 loop (Esbaugh and Tufts 2006). 
 
The central role of HCAII in interaction with HCO3- transporters has been clearly 
demonstrated additionally it has been shown that also the extracellular isoform CAIV 
can bind the AE1, AE2 and AE3. HAE1 together with CAIV and CAII on both sides 
of the membrane generate a “pull- push” mechanism for bicarbonate transport 
(Sterling, Alvarez et al. 2002) (Figure 6). 
 
 
 
 
 
 
 
 
 
 
Figure 6: “Pull- Push” mechanism of CAII and CAIV (Sterling, Alvarez et al. 2002) 
 
CA- mediated production of bicarbonate presents the “push” while the conversion of 
bicarbonate to CO2 provides the “pull”- mechanism.  
It is rather surprising that the lack of CAII is characterized by renal tubular acidosis 
and osteopetrosis while a sufficient CO2 transport capacity is still maintained. This 
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could be due to the expression of CAIV in erythrocytes. Osteoclasts do not express 
CAIV and in kidney the presence of CAIV is not sufficient to reabsorb bicarbonate 
from the renal tubular lumen and prevent tubular acidosis (Sterling, Alvarez et al. 
2002). 
 
1.2.3 The Capno metabolon as a model for bicarbonate transport 
metabolons 
 
CA and bicarbonate transporters have a central role in a variety of tissues. Miss-
regulation of bicarbonate transporters can be the reason for serious diseases like cystic 
fibrosis (SLC26A6 bicarbonate Transporter).  
It is rather likely that not all HCO3- transport metabolons are have been discovered so 
far. The majority of the interaction studies focused on CAII, but it is highly probable 
that also other carbonic anhydrases like the membrane- bound CAIV are involved in 
such systems. 
The role of the binding site concerning the shuttling of HCO3- to the transporter or 
HCAII is still not clear. Therefore structural insight into the capno metabolon could 
lead to a deeper understanding of bicarbonate transporter metabolons in general. 
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1.3 Objectives for this study 
 
The aim of this study is structural investigation of the binding of human carbonic 
anhydrase II (HCAII) to the C-terminal cytoplasmic region (33 amino acid residues) 
of human anion exchanger 1 (HAE1). We employed as principal structural biology 
techniques crystallography and NMR. Co- crystallization and crystal soaking of 
HCAII as well as titration studies followed by NMR will be performed.  
Sample preparation comprised expression and co-expression in E. coli, purification 
and complex formation.  
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2 Methods and Materials 
2.1 Cloning 
2.1.1 PCR 
 
The primers were designed with BsaI restriction sites: 
HCAIIF1 (forward) 
5'                                                                                      3' 
AATTGGTCTCCCATGTCCCATCACTGGGGGTAC 
HCAIIR2 (reverse) 
5'                                                                                           3' 
GGTACCGAGACCTTATTTGAAGGAGGCTTTGATTG 
The cursive letters show the BsaI restriction sites. 
 
PCR- Mixture: 
1µl template (40 ng/µl) 
0.5µl Primer 1 (10 pM; Sigma) 
0.5µl Primer 2 (10 pM; Sigma) 
0.2µl Taq (1u/µl; Fermentas) or Pfu (1u/µl; Fermentas) 
2µl 10×Polymerase Buffer (Fermentas) 
1.6µl MgCl2 (25 mM; Fermentas) 
2µl dNTPs (2 mM; Fermentas) 
12.2µl H2O 
20µl 
 
PCR- Program: 
Step Temperature Time Cycles 
Initial Denaturation 94°C 4min. 1 
Denaturation 94°C 30sec. 24 
Primer Annealing 55°C 30sec. 24 
Elongation 72°C 1min. 24 
Final Elongation 72°C 5min. 1 
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The most efficient temperature of Primer Annealing was defined by gradient PCR 
(50, 55 and 60°C). 
2.1.2 DNA- Purification after PCR 
 
The Purification of PCR- Product was done with a PCR- Purification Kit (Quiagen). 
DNA was eluated in 30µl H2O. 
2.1.3 Double Digest of pETM 13 with Acc65I and NcoI 
 
5µl plasmid pETM-13 (200 ng/µl) 
0.5µl NcoI   (10u/µl; Fermentas) 
1µl Acc65I (10u/µl; Fermentas) 
4µl 10×Tango Buffer (Fermentas) 
9.5µl H2O 
20µl 
The double amount Acc65I was used because it has only 20-50% activity in Tango 
Buffer. The mixture was put 3h on 37°C. No heat inactivation is necessary because 
this digest is followed by a gel extraction. 
2.1.4 Digest with BsaI 
 
30µl PCR – Fragment (directly from PCR- Purification) 
1µl BsaI (10u/µl;  BioLabs)  
4µl NE 3 Buffer ( BioLabs)  
5µl dH2O 
40µl  
 
The mixture was put 3h on 50°C and was followed by 20min. on 60°C (heat 
inactivation). 
2.1.5 Digest with EcoRV 
 
5µl pETM- 13 
0.5µl EcoRV (10u/µl;  Fermentas)  
1.5µl NE 3 Buffer ( BioLabs)  
  
27
9.5µl dH2O 
16.5µl  
 
The mixture was put 3h on 37°C and was followed by 20min. on 85°C (heat 
inactivation). 
2.1.6 Determination of DNA concentration 
 
DNA- concentration was measured with a UV- spectrometer at 260nm. It gives the 
value in µg/ml.One absorption unit corresponds to 50 µg/ml. The absorption has to be 
divided with the absorption at 280nm. The ratio of pure DNA is >1.9. 
2.1.7 Ligation 
 
8µl fragment (molar ratio between vector and fragment is always 1 : 3) 
1µl vector (60 ng) 
1µl 10×ligase buffer (Fermentas) 
0.5µl ligase (5Weiss u/µl; Fermentas) 
10.5µl 
 
The ligase- mixture was put on 16°C over night. The ligase was inactivated by 
incubation for 20min. at 60°C. 
2.1.8 Preparation of competent cells 
1. Prepare a preculture with adequate antibiotics and let it grow over night. 
2. Prepare a cell culture using LB medium and add 10 mM MgCl2, 0.2% 
Glucose and adequate antibiotics. 
3. Inoculate the with preculture adding 1/100 of the new culture volume. 
4. Grow the cells to OD~0.4. 
5. Centrifuge the cells gently and resuspend the pellet in ice cold RF1 of 1/3 of 
the original volume. 
6. Incubate on ice for 15`up to 2h. 
7. Centrifuge the cells gently and resuspend the pellet in ice cold RF2 of 1/12.5 
volume of the original cell culture and store on ice for 15min. 
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8. Aliquote the cell culture in 100µl Eppendorf tubes and freeze then in liquid 
nitrogen. Store on -80°C. 
2.1.9 Transformation 
 
The whole ligation- mixture was added to 50µl of competent cells. For positive 
control the same was done with 1µl (~100ng/µl) of empty vector. 
1. 30 min. on ice 
2. 90 sec. on 42°C (heat shock) 
3. 1 min. on ice 
4. add 1ml of LB media and shake 1h on 37°C 
5. spin 5min. at 6000rpm 
6. remove 1ml and gently resuspend the pellet  
7. plate the cells on Agar plates with the proper antibiotics and let grow over 
night on 37°C in the incubator 
 
2.1.10 Agarose- Gel 
 
Always 1% Agarose- Gels (Standard Agarose) were used which can efficiently 
separate fragments between 250bp and 12kbp.  
 
Pouring the gels: 
1. Add 0.3g Agarose to 30ml TAE – Buffer and heat it in a microwave till the 
agarose is completely dissolved 
2. Enclose 1µl of Ethidiumbromid per ml Agarose and pour the gel 
 
After the gels have cooled down they can be used. All gels were run in TAE- Buffer 
on 90V for ~ 25min. DNA- bands can be visualize by intercalated Ethidiumbromid 
under UV.  
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Sample preparation: 
2µl DNA 
3µl H2O 
1µl 6×Loading dye (Fermentas) 
6µl  
 
To estimate the size a 1kbp Marker (Fermentas; O´Gene Ruler 1kbp DNA Ladder 
ready- to use) was used.  
2.1.11 Gel Extracation 
 
A Kit (Qiagen) was used for this purpose. DNA was eluted in 30µl H2O. 
 
2.1.12 Preculture 
 
Inoculate a single culture from a plate or a small clump of glycerol stock in 20ml of 
LB media or strike out on a plate and let it grow over night on 37°C. Use the adequate 
antibiotics.  
2.1.13 Colony PCR 
 
It is a method to prove if a colony has the plasmid with the right insert. 
Add a colony to 50µl H2O and put it for 5min. on 96°C. Then use this as template for 
PCR.  
2.1.14 Mini- Prep 
 
A Kit (Fermentas) was used. 
2.1.15 Freezing cells 
 
Glycerol was added to the cell to a final volume of 25%. The cells were stored at -
80°C. 
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2.2 Proteinexpression and Cell lysis: 
2.2.1 Expression Screen 
 
The expression of a protein differs dependent on the used cell strain. Therefore it can 
be really important to choose the right bacterial strain to get a sufficient amount of 
protein. The expression screen makes it possible to do small scale expressions a high- 
throughput way (Groves and Lodge, manuscript in preparation) by usage of 
autoinduction- media. The bacteria are induced after the have used all the glucose and 
therefore have to switch to lactose. 
 
A. Transformation: 
The Transformation is performed in a 24- deep well plate. A typical set up could look 
like this. 
 Strain 1 Strain 2 Strain 3 Strain 4 Strain 5 Strain 6 
Vector 1       
Vector 2       
Vector 3       
Vector 4       
 
Therefore four different vectors coding for different proteins or the same proteins with 
different tags could be combined with six different bacterial strains. 
 
Do the following procedure for every well of 2 plates because one is put on 20°C and 
one on 37°C. 
 
1. 1µl DNA  is added to 50µl of competent cells 
2. Put it 30min. on ice 
3. 45-60 sec. on 42°C (do this in water bath) 
4. 5min. on ice 
5. add 1ml of autoinduction media  
6. Put 1h on 37°C  
7. Add the proper antibiotics (dilution 1:1000) 
8. One tray on 37°C and one on 21°C and let them grow over night 
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B. Harvesting and dot blot 
The bacteria are harvested and by a dot blot the amount of expressed protein is 
estimated. 
 
1. The bacteria are transferred to a 96- well- filter plate in duplicates (so there is 
enough space for two 24well plates on one 96- well format) 
2. Centrifuge for 5min. at 500g in a swing- plate rotor 
3. Add 25µl of lysis buffer 
a. Bug buster (Novagen) in first of dublicates; 
b. Denaturating buffer in second of duplicates; 
4. Shake 20min. at room temperature on a gel shaker at 200rpm 
5. Centrifuge at 500g for 5min. and collect the filtrate in a new plate 
6. Add 2µl of the filtrate to a nitrocellulose membrane and let the membrane air 
dry 
7. Incubate the membrane in 20ml blocking solution for 1h (1%BSA in TBST) 
8. Remove blocking solution  
9. Incubate the membrane with 1st antibody diluted 1:2000 in TBST for 1h 
10. Remove antibody solution 
11. Wash the membrane 3× 10min. in TBST 
12. Incubate membrane with  2nd antibody (conjugated to alkaline phosphatase) 
diluted 1:3000 in TBST for 1h 
13. Remove the antibody solution 
14. Wash the membrane 3× 10min. in TBST 
15. Develope the membrane in 10ml of colour- development buffer containing 
100µl NBT and 100µl BCIP 
16. Incubate and shake gently until colour develops, wash with water to stop the 
reaction 
 
The first of the duplicates will show the soluble part of protein because the bug buster 
mix only opens the outer membranes and the cytosolic protein can leave the cell 
during centrifugation. The second dublicate shows the complete amount of protein 
because soluble as well as unsoluble protein is extracted by denaturating buffer. 
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2.1.2 Large Scale expression and harvesting 
 
20ml Preculture and antibiotics (dilution 1:1000) were added to 1l 1× (his-trx-HAE1) 
or 2× LB (HCAII). For the expression of HCAII 0.5 mM ZnSO4 has to be added. 
(Zn2+ is in the active site of HCAII). The initial OD should be ~0.05. The bacteria 
were grown at 37°C till they reached an OD around 0.6. Then they were induced with 
0.5 µM IPTG and were incubated 4h more on 37°C. An alternative way was to grow 
them over night on 30°C. Then the cells were spun for 15min. at 10 000g. Then the 
bacteria were resuspended in 20-40ml buffer for the following first purification step 
and stored on -80°C. 
2.2.3 Large Scale expression and harvesting of labeled protein for 
NMR 
 
The same protocol like for unlabeled proteins but expression in M9- Minimal media.  
2.2.4 Cell lysis 
 
One part of cell lysis was to freeze the cells on -80°C and thaw them again. (Freeze- 
thaw- cycle) This was followed by 10 min. sonication with pulses of 2 sec. with a 
pause of 8 sec with strength of ~60%. After this the cell-lysate was spun for 30 min. at 
20 000g. The supernatant was used for purification.  
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2.3 Purification 
 
All columns (accept the gravity columns) were connected to ÄKTA Purifier 
(Amersham Bioscience). 
2.3.1 Affinity chromatography 
 
Affinity chromatography is based on a matrix- bound molecule which can “fish out” 
its specific binding partner. The affinity should be between 10-5 and 10-7M. Stronger 
binding makes it hard or even impossible to elute the binding- partner from the resin. 
This is normally done by a competitive partner or conformational changes of the 
binding partner due to changes in pH or ionic change. 
 
2.3.1.1 IMAC 
 
A special sort of affinity chromatography is the IMAC (immobilized metal chelating 
affinity chromatography). Here a metal chelating- group is bound to the resin. In this 
way different metals like Cu2+, Ni2+, Zn2+, Co2+, Fe2+ or Fe3+ can be immobilised to 
the matrix. The most common method of IMAC is the purification of his- tagged 
proteins on a nickel column. The 6 histidines are coordinated by the nickel and can 
bind in this way to the column. The tagged protein is eluted with imidazol which 
competes with the his - tag for Ni. It is advised to add some imidazol during 
equilibration and washing of the column to exclude unspecific interaction. Intensive 
used resin can be regenerated with NiSO4 after removing the used nickel with an 
EDTA- containing buffer (stripping buffer). 
 
2.3.1.1.1 Gravity flow nickel column 
 
A gravity nickel column (Biorad) was used which was manually loaded with nickel 
sepharose. (2ml/1l expression) The protein was loaded 3 times and washed once with 
lysis buffer. 6-12 Fractions were eluted with elution buffer depending on the visible 
colour- change of the resin. For buffers see Buffer list. 
 
2.3.1.1.2 Nickel column on ÄKTA 
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A His Trap HP 5ml (Amersham Bioscience) column was used. The column was 
equilibrated with Buffer A. The protein was eluted over 20 column volumes with a 
gradient up to 80% Buffer B. For buffer see Buffer list. 
2.3.2 Ion- Exchangers 
 
Ion- Exchangers are based on the amphoteric character of amino acids. In acidic 
environment lysine, arginine and histidine are positive charged whereas aspartate and 
glutamate are negatively charged in basic pH-environment.The isoelectric point is 
defined as the pH at which the proteins has no charges at all. Therefore a protein is 
positive charged in an acid buffer (pH < pI) and negative charged in a basic buffer 
(pH > pI) (Figure 7).  
This is exploited by ion- Exchangers. In cation exchangers positive charged proteins 
bind to the negative charged resin and are eluted by an increasing gradient of cations 
in salt. For anion exchangers the principle is the same but here the protein is 
competing with anions. 
 
 
Figure 7: Use of anion- or cation exchangers dependent on the pH of the buffer (Rosenberg 2005) 
 
The more unequal the pH of the buffer is to the pI, the stronger the protein can bind to 
the resin. The pH should at least be +1 or – 1 of the pI. Posttranslational modifications 
and conformational changes can have effect on the elution volume because they can 
charge distribution on the surface of the protein. 
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2.3.2.1 Cation- exchanger 
 
A SP Sepharose FF (Amersham Bioscience) was used. 
The column was equilibrated with Buffer A + 20 mM (NH4)2SO4. The protein was 
elutated by an increasing salt gradient up to 1M over 10 column volumes. 
For buffers see Buffer list. 
 
2.3.2.2 Anionexchanger 
 
A Hi Trap Q FF 1ml (Amersham Bioscience) column was used. The sample was 
always loaded two and sometimes even three times when the column was still 
overloaded. 
The protein was eluted over 10 column volumes with a gradient starting with Buffer 
A and ending with 50% Buffer B. 
For buffers see Buffer list 
 
Resource Q (5ml; Amersham Bioscience) was also run. Same buffer where used like 
for HiTrap Q FF 1ml but without β- Mercaptoethanol. A gradient over 25 column 
volumes up to 100% Buffer B was used. 
 
2.3.3 Hydrophobic Interaction Chromatography 
 
HIC is a combination of a non- denaturing salt precipitation and a chromatographic 
separation-method. The surface tension is increased by chaotropic salt and therefore 
the hydrophobic regions of the protein are exposed to the surface. These hydrophobic 
areas can interact with the hydrophobic resin. Normally alkyl- or phenyl groups are 
used for this purpose. The proteins are eluted by a decreasing gradient of salt. 
Normally (NH4)2SO4 is used as salt- compontent because it has a chaotropic and 
“salting out”effect and is in this way supporting the hydrophobic interaction. 
 
Protocol: 
A Phenylsepharose – column (Amersham Bioscience) was used for the second step of 
HCAII purification 
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For this the concentration of (NH4)2SO4   had to be increased to 2 M. The (NH4)2SO4 
has to be added slowly and on ice. Then the sample was centrifuged for 30min. 20 
000g to remove precipitate.  
 
 
The column was equilibrated with Buffer B. The protein was eluted by a decreasing 
gradient of salt to 0 M over 10 column volumes. For buffers see buffer list. 
 
2.3.4 Size exclusion chromatography (Gelfitration) 
 
SEC can separate proteins due to their size. The column is filled with a densely 
packed porous matrix. Proteins larger than these pores do not enter them and will be 
eluted at the dead volume. Smaller proteins penetrate the pores and will be eluated 
later. The smaller the protein the bigger is the maze of pores and the longer it will take 
them to leave the column. Therefore it is important to choose a column with the right 
size of pores (Table 1). 
 
Table 1:Types of Gelfiltration columns and their separation ranges; (biotech) 
 
 
Protocol: 
A Sephadex 200 26/60 column (Amersham Bioscience) was used for the final steps in 
purification of his- trx – HAE1 and HCAII. 5ml sample were loaded with a sample 
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loop on the equilibrated column and elution was done over 1.5 column volumes.For 
buffers see Buffer list. 
 
2.3 Analysis 
2.3.1 Determination of Protein concentration by UV- Spectrometry  
 
Different dilutions of protein in 6 M Guanidine- hydrochlorid were prepared. Then 
the samples are measured with a UV- spectrometer at 280nm. 6 M Guanidine- 
hydrochlorid was used as blank. 
 
Following Lambert- Beers- Law: 
 
 
Measured values smaller then 0.1 or bigger then 1 were not used because out of these 
borders Lambert- beers- Law is not valid any more.  
 
 
2.3.2 SDS- PAGE 
 
For casting gels see Materials and Methods 
 
The Gels were run at 190V for 30-45min. till the blue front has reached the end of the 
glass plate. Then they were stained with Coomassie or the more sensitive Zn- 
Imidiazol- Staining. 
 
2.3.2.1 Coomassie- Staining  
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Coomassie binds at acidic environment to the positive charged amino acids lysine, 
histidine and arginine. In the rest of the gel coomassie diffuses out when treated with 
destaining solution. Around 100ng /band can be detected. For buffers and solution see 
Buffer list. 
 
2.3.2.1 Imidazol- Zink- Staining 
 
This reverse staining method is around 10× times more sensitive than Coomassie 
staining and much less time consuming than silver staining. Imidiazol- Zink- staining 
is a very gentle method that does not require strong acid solutions, organic dyes and 
chemical modifiers. So the proteins can be eluted and used in biological and 
enzymatic assays. 
 
The method exploits the ability of proteins to bind Zn2+ and of imidazol to react with 
unbound Zn2+ to produce insoluble zinc- imidazolate. 
The background of the gel is therefore deep- white while the protein bands are 
transparent. 
 
1. Rinse the gel for a few seconds in dH2O 
2. Equilibrate the gel in 50 to 100ml 0.2 M Imidazol- solution; time of 
this step depends on the percentage of the gel (10%PAGE 5min.; 
12.5%PAGE 10min.; 15%PAGE 30min.)  
3. Discard the imidazol- Solution 
4. Stain the gel in 50- 100ml 0.3 M ZnCl- Solution 
5. Discard ZnCl- Solution when the background becomes deep white or 
dark blue with transparent protein bands 
6. Store the reverse- stained gels in dH2O 
 
2.3.3 SDS- Urea- Gels 
 
Urea- Gels can be useful when the mobility of small proteins on SDS- gels is no 
longer proportional to their molecular weight.  
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 X% Seperation Gel X% Stacking Gel 
30% Acrylamid- Mix X/3 ml  X/7.5ml 
1.5 M Tris- HCl pH=8.8;0.4% SDS 2.5ml  0ml 
0.5 M Tris-HCL pH=6.8; 0.4% SDS 0ml 1ml 
Urea 4.8g 1.9g 
H2O 3.9 - X/3ml  1.6- X/7.5ml  
10% APS 50µl 30µl 
TEMED 5µl 5µl 
 
All buffers and procedures are the same as with SDS- PAGE. 
 
2.3.4 Western – Blot  
 
A SDS PAGE is blotted on a nitrocellulose- membrane. With antibodies a special 
protein or a part of it can be detected. 
 
1. Run one gel for Western blotting and one for Coomassie- staining  
2. Equilibrate a suitable size of membrane and soak 2 sponges and 2 pieces of 
filterpaper in Western- Transfer- Buffer (Touch the membrane only with 
tweezers) 
3. Now build the Transfer- “Sandwich” beginning from the anode in the 
following order together:  
 
a. Sponge 
b. Filter 
c. Gel  
d. Membrane 
e. Filter 
f. Sponge 
            The proteins travel from the cathode (black) to Anode (red). 
 
  
40
4. Place the cassette in the holder with ice cold Transferbuffer and run the blot 
for 1h at 100V while stirring; disassemble the sandwich and stain the gel as a 
transfer control 
5. Block the membrane at least for one hour in 10-20ml in Blocking solution  
6. Wash 3×10min. in 20ml TBST 
7. Incubate for 1h  with 1st antibody (anti- his- tag antibody) 
8. Wash 3×10min. in 20ml TBST 
9. Incubate for 1h with 2nd antibody 
10. Wash 3×10min. in 20ml TBST 
11. Develop the blot in 10ml Development buffer containing 100µl NBT (stored 
on –20°C) and 100µl BCIP (stored on –80°C)  
12. Shake gently till the colour develops and the wash with water to stop the 
reaction 
2.3.5 Expression and Purification of TEV  
 
1. Transformation of Vector in BL21plysS 
2. Prepare 5ml overnight culture with LB containing 1% Glucose, Kanamycin and 
Chloramphenicol  
3. Inoculate overnight culture in 1l LB  
4. Grow to OD ~0.5-0.8 
5. Cool down and then induce with 1ml 0.5 M IPTG 
6. Harvest cells and weight pellet 
7. Dissolve cells in 10ml Lysisbuffer/g wet pellet 
8. Sonicate 10min. 2cycles at 40% power on ice 
9. Spin down 20min. 5000g  
  
Nickel column 
1. Add 1/1000 Expression Volume of Ni Sepharose to a gravity column 
2. Wash with water and equilibrate with lysis buffer  
3. Decant supernatant an Ni column 
4. Reload flow through twice on Ni column 
5. Wash with 10 column volumes lysis buffer, wash1, wash2 and wash 3 
6. Elute with 5 column volumes elution buffer 
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7. Measure the concentration of TEV and run a gel  
8. Dilute it to 1mg/ml with glycerol 
9. Freeze aliquots in liquid nitrogen and store them on -20°C  
 
 2.3.6 Cleavage with TEV- protease 
 
The samples were cleaved with 100µl TEV (1mg/ml) over night at 4°C. Sometimes 
the buffer conditions where really unfavourable (pH < 8) but could not be changed. 
Therefore more TEV was added or the cleavage was begun with 15min. on 37°C or 
RT and completed on 4°C.  
If the sample contained imidiazol cleavage was done during dialysis.  
 
2.3.7 Protein- Concentration 
 
The Concentration – Steps were done with Centriprep – Devices (Millipore). For 
volumes smaller than 1ml “Ultrafree- MC” (Millipore) were used. 
 
2.3.8 Dialysis 
 
Volumes bigger then 3ml were dialyzed with   “molecular porous membrane tubings” 
(Spectrumlabs), while for smaller volumes the Slide-.A- Lyzer – Kit (Pierce) was 
used. Always a cut- off at least 3 times smaller then the protein was used. A typical 
Dialysis protocol was to begin the dialysis in the morning change the buffer in the 
evening and dialyze over night. 
 
2.3.9 Aceton- Concentration 
 
300µl sample were mixed with 1.5ml ice- cold acetone and put for 30min. on -20°C. 
Then the sample was centrifuged for 15min. on maximal speed on 4°C. The 
supernatant was discarded and the pellet was spun in a speed vac for 15min. to 
remove the rest of acetone. The pellet was dissolved in 10µl dH2O and 10µl 2×sample 
buffer and loaded on a SDS PAGE. 
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2.3.10 Thermofluor 
 
Thermofluor is a high through put method to determine the conditions (buffer, pH, 
additives…) in which a protein is most stable. Thermostable proteins have a lower 
prospensity to aggregate, unfold or undergo proteolysis. Changes of conditions can 
dramatically increase or decrease thermostablility. It was proved that thermostable 
proteins also have a higher probability to crystallize(Ericsson, Hallberg et al. 2006; 
Vedadi, Niesen et al. 2006). 
 
The method is based on the properties of the hydrophobic fluorescent dye SYPRO 
ORANGE. It is quenches by water unless interacting with hydrophobic components 
like the hydrophobic core of unfolding protein (Figure 8).  
 
 
Figure 8: Dye unbound to native protein; Dye bound to heat denaturated protein 
(http://lab-robotics.org/Presentations/Kranz%200509/05LRIG_JKKranz-seminar.pdf (2.07.07)) 
 
The protein is heated in descent steps and the fluorescence is measured. As long as the 
protein is stable, low fluorescence should be detected. Sooner or later the increase in 
temperature leads to heat denaturation of the protein and to sigmoid rise of 
fluorescence because the dye can now bind to the exposed hydrophobic regions. The 
inflection point of this curve is defined as the melting point (Figure 9). 
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Figure 9: Melting curves measured by thermofluor (Ericsson, Hallberg et al. 2006) 
 
The melting points (Tm) of protein in different conditions are determined and 
compared. The farer the curve is shifted to the right (higher temperature) the more 
stable the protein is in that condition. The condition with the highest Tm is most 
suitable to stabilize the protein.  
The method requires a machine which can measure fluorescence and can heat the 
sample in well defined steps. The most suitable system is a RT-PCR machine. 
Because there is no fluorescent dye used in RT- PCR with similar extinction and 
emission, therefore a combined filterset had to be used (Figure 10). The excitation 
filter of FAM (490nm) and the emission filter of ROX (575nm) are used. 
 
Figure 10: Excitation- (left) and Emissionspectrum (right) of SYPRO Orange 
(http://www.bio.indiana.edu/~ybelab/procedures/SyproOrange.pdf (2.07.07)) 
 
Protocol: 
The method is done with 96- well RT- PCR plates. Transparent or white ones can be 
used. Masterplates with different buffers, ionic strength or additives can be prepared 
and transferred to the 96 wells sample plate.  
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5µl protein (2.5mg/ml) 
7.5µl SYPRO ORANGE 5000 100×diluted  
12.5µl 2 × Masterplate condition  
25µl 
 
The proteins were heated in steps of 1°C from 25°C to 95°C. In every step the 
fluorescence was measured.  
 
2.3.11 Crosslinking 
 
Two ways were tried. 
 
2.3.11.1 Crosslinking with BS2G 
 
This crosslinker can connect all different Lysines and Aminotermini of proteins and 
Peptides as long they come close enough. The crosslinking agent is available in the 
heavy and the light form that means that in the heavy form two carbons of CH2 – 
groups are converted to CD2 (Figure 11). The deuterated and the non- deuterated form 
are used for crosslinking in a ratio 1:1. Tryptic digested crosslinking products 
analyzed by mass spectrometry contain peptides showing a difference of 4 units. This 
difference results from the mass difference of the crosslinkers and makes it possible to 
identify the sites of intra- and intermolecular interactions.  
        
 
Figure 11: BS2G-d0 and BS2Gd4;  
(http://www.piercenet.com/products/browse.cfm?fldID=3F8F9D3C-2764-44DE-A005-
CCB856AB5696  5.11.07) 
 
 
  
45
Protocol: 
The reaction is pH sensible and will be impeded at a pH < 6. It is also important to use 
no buffer components with NH2 - or SH- groups. 
 
→200×crosslinker: 2mg heavy and 2mg light crosslinger in 40µl DMSO 
 
For the crosslining of the complex (HCAII and HAE1ct ) 10 times higher protein 
contration and crosslinker were used than for the positive control because otherwise 
the complex would not be visible on a coomassie- stained  SDS- PAGE. The complex 
was formed in Gelfiltration buffer and then diluted with crosslinking buffer for the 
reaction. 
α- actinin (103 kDa) was used as a positive control because it is known to form a 
homodimer and it is very likely that in this case Lysines or Amino- termini come near 
enough to be crosslinked. 
HCAII instead of the complex was used as a negative control because it should not 
interact with itself. 
 
Sample: 
3µl Complex (Final conc. = 20 µM) or HCAII 
3µl 200× Crosslinker 
94µl 20mM HEPES pH=7.5 20mM NaCl  
100µl 
 
Positive control: 
17µl α- actinin (0.6 µM) 
3µl 20×crosslinker 
80µl 20mM HEPES pH= 7.5 20mM NaCl  
100µl 
 
The samples were put over night on 4°C. Next day the reaction was stopped by adding 
5µl of Ammonium bicarbonat and the samples were put 15min. on ice. Afterwards the 
crosslinking was checked on 10 and 12% SDS- PAGE. 
The reaction can be optimized by changing time, concentration of crosslinker and 
temperature.  
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2.3.11.2 Crosslinking with Formaldehyd 
 
Formaldehyd is used for unspecific crosslinking of cells and tissue slices. In lower 
concentration it can also be used to crosslink interacting proteins in solution (Figure 
12).  
 
 
Figure 12: Mechanism of Crosslinking by Formaldehyd 
 
Protocol: 
The Products of this reaction are acid- instable and therefore a basic buffer should be 
choosen. To compare the results with the BS2G crosslinking a rather similar buffer 
(20 mM HEPES pH=8; 20 mM NaCl) was chosen. Again α- actinin (0.6 µM) was 
used as a positive control. 
 
The complex of HCAII and HAE1ct was formed in same concentration in 
Gelfiltration buffer and then diluted to 20 µM with the crosslinking buffer. 
 
Concentrations between 0.25 and 2% of Formaldehyd were added and after 2h on RT 
aliquots were taken and loaded on a 10 and on a 12% SDS PAGE. α- actinin was 
crossinked with 1% and HCAII with 2% of Formaldehyd. 
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2.4 Determination of Structure 
 
2.4.1 Crystallography 
 
Macromolecular crystallography is a method to determine the 3- dimensional 
structure of proteins and other macromolecules by the visualisation of the electron 
density. The first and maybe most challenging barrier are to get crystals. They are 
built of symmetrical units highly ordered in three dimensions. Every crystal can be 
reconstructed by its unit cell as a basic module and some clearly defined symmetrical 
operations. Because of their high symmetry crystals behave in the x- ray beam like an 
amplifier of the unit cell and make it possible to get enough information for structure 
determination. In difference to salt crystals protein crystals are not rigid because they 
contain 20-80% water and the proteins are still relative flexible. 
 
2.4.1.1 Growing crystals 
 
The principle of growing crystals is to decrease the solubility of the protein in the way 
that it forms nuclei (seeds for crystals) but does not precipitate. In the small zone 
between solubility and precipitation crystal seeds can form and grow. Also the right 
equilibrium between seeding and growing is required. An overhang of nucleation 
gives rise to a lot of small useless crystals (Figure 13).  
 
Figure 13: Phasediagram of nucleation and crystal growth (Gale 2006) 
 
The most common used precipitants are ammonium sulphate and PEG (available in 
different length). Salts like ammonium sulphate precipitate proteins by competing 
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with them for the water shell. This is a process called salting out. Organic components 
like PEG lower the dielectric constant in solution and precipitate proteins in this way. 
Methods of setting crystallization drops are sitting drop, hanging drop, under oil batch 
or “dialysis”. The most popular are sitting and hanging drop (Figure 14). 
 
 
Figure 14: Sitting drop method;(Gale 2006) 
 
2.4.1.2 Phasing 
 
The second barrier is to determine the phases of the structure factors which are 
measured by the x- ray experiment.  They are a necessary input for the Fourier- 
Transformation which transforms the reciprocal space (experimental x-ray pattern) 
into the real space (electron density of protein). Different methods can be used: 
 
1. Isomorphous replacement:  
Heavy atom derivates of the crystals have to be produced and are compared to 
the native dataset. From their difference the phases can be extracted. 
2. Anormalous scattering: 
Variable wavelength synchrotron radiation is used to collect dataset at 
different wavelength. The different datasets are treated like native protein and 
derivates. Like in isomorphous replacement this can be used to determine the 
phases. 
3. Molecular replacement: 
The structure of a homolog protein or a domain of the protein of interest has to 
be known. This can be used to extract the phases.  
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The Fourier- Transformation based on the input of structure factors and phases gives 
an electron density map (Figure 15). The amino acids can then be fitted in.  
 
Figure 15: Electron density (left); amino acid structures filled in electron density (right);(Gale 
2006) 
 
Protocol: 
The initial screens were done with the crystallization robot. Crystalquick Plates 96 
wells (Greiner) were used. It is possible to set 3 drops in these plates. A program was 
used which set drops of 100nl in ratio (protein: Crystal screen) 1:1 or 1:2. One place 
stays free. For the Refinement EasyXtal tool (NeXtal) 24 well plates were used. 1µl 
of Protein- solution was mixed with 1µl Crystallization Solution. The volume in the 
reservoir was 1ml. The data was measured with our home facility (Bruker proteum 
X8) or at ESRF Grenoble. 
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2.4.2 NMR: (Nuclear magnetic resonance) 
 
Molecules placed into a magnetic field have a bulk magnetization along the z- axis 
(direction of the magnetic field). This magnetization consists of small magnetic fields 
due to nuclei which also have nuclear spin magnetic moment µ. When these nuclear 
moments experience the magnetic fields they can have high or low energy 
orientations depending on their angle to the magnetic field. In equilibrium the net 
magnetization of the chaos of “tiny nuclear magnets” is pointing into the z- direction 
(direction of the magnetic field) because it is energetically more favourable (Figure 
16). 
 
Figure 16: Dependence of energy on orientation to magnetic field (left); Assembling of net 
magnetization over time (right); (Keeler 2005) 
 
This equilibrium can be disrupted by the application of a Radiofrequency- pulse. 
Dependent on the duration and frequency of the pulse and strength of the magnetic 
field, the net magnetization can be “turned” into the y- axis and a signal can be 
detected by coils. This signal is called FID (= Free induction decay). The FID can be 
processed by the Fourier- Transformation that the time domain is changed into 
frequency domains which can then be assigned to specific groups of the molecules 
(Figure 17). In this way their structure can be determined. 
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Figure 17: 1D- pulse sequence (left); Fourier- transformation of time domain (FID) to frequency 
domain (right); (Keeler 2005) 
 
Not every nucleus is sufficient to contribute to the net magnetization. It is necessary 
that they have a nuclear spin quantum number I. This is normally the case when the 
nucleus has an unequal number of protons. Typical elements used for macromolecular 
NMR (proteins, RNA, DNA) are H1, N15 and C13. Therefore for 2- or 3 dimensional 
NMR studies proteins are expressed in minimal medium containing the rare isotopes 
like N15 and C13. 
 
2.4.2.1 Two dimensional NMR- experiments for proteins 
It is also possible to record multi- dimensional spectra. These NMR experiments have 
more complex pulse- sequences than 1D- experiments which include evolution times, 
where the signal that is recorded in t2 is affected by what happens in t1.  
 
 
Figure 18: 2D- pulse sequence (left); Increasing t1 in defined increments (right); (Keeler 2005) 
 
A 2D- spectra is produced by recording an array of 1D FIDs, where i.e. t1 is 
successively extended by the increment ∆1 (Figure 18), and performing Fourier- 
transformation in both directions (t1 and t2). 
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A common used 2D- method is the HSQC (= Heteronuclear Single- Quantum 
Correlation). Here magnetisation is first transferred from H1 to N15 and allowed to 
evolve (t1), then magnetization is transferred back to H1 where it is allowed to evolve 
while the FID is recorded (t2). Only parts of the protein were hydrogen and nitrogen 
are coupling are detectable. So it is possible to see the NH- group of the backbone of 
every amino acid, despite of prolines, as well as amino groups of asparagines, 
glutamine and Lysine (Figure 18). 
 
2.4.2.1.1 Binding Titrations 
Since the chemical shift is very sensitive to differences in electronic structure, binding 
studies are straight forward in NMR- spectroscopy. Peaks that change their position 
(either upfield -to low ppm -or downfield - to high ppm) due to titration with an 
unlabeled ligand are therefore affected by changes in their electronic environment. 
Therefore, it is possible to determine the interaction site, as well as determination of 
binding constants 
 
Figure 19: HSQC (left); HNCA or HNCOCA – spectra in 3rd dimension of HSQC (middle); path 
of magnetization transfer in HNCA and HNCOCA (right)  
(http://www.public.iastate.edu/~bfulton/instructions/hsqc_3919.html (3.7.07)) 
(http://en.wikipedia.org/wiki/Image:Hncahncoca.jpg  ) 3.7.07))  
 
2.4.2.2 Three dimensional NMR- experiments 
 
3D NMR experiments are similar working like 2D but here one evolution time more 
is introduced and the result is a 3- dimensional cube of information. Here the coupling 
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between N15, C13 and H1 is for example detected. Therefore the HSQC just gets a new 
dimension (C13- shifts). These experiments differ by the “path” of magnetization 
transfer in the backbone which is controlled by the used coupling constants. For 
example in hncoca the magnetization is transferred for hydrogen to nitrogen then to 
the carbonyl- groups and finally to the Cα- carbon. 
 
By the combination of different 3D experiments (for example HNCA + HNCOCA or 
CBCACONH and HNCACB) and the primary sequence of the protein, every peak in 
the HSQC could be assigned to a position in the primary sequence of the protein (= 
backbone assignment). In this way it is possible to identify the amino acids which are 
shifted by the binding of a ligand or oligopeptide. To determine the 3D structure of 
the protein, addition measurements are needed: first, all resoncances (also from side 
chains) have to be assigned and finally distance measurements (NOESY spectra) are 
needed.  
 
2.4.2.2.1  NOESY 
 
Two spin can couple either via chemical bonds or directly via space. Latter is called 
dipolar coupling and is the basis of the so called Nuclear Overhauser Effect (NOE). 
This effect is dependent on distance and decreases with its power to 6.Therefore only 
interactions closer than 3Å can be measured. Amino acids coming close to each other 
not due to adjacency in primary sequence but due to adjacency in space deliver 
therefore an not expected NOE, which can be used to figure out the three- 
dimensional structure. 
 
Protocol: 
For 2D Experiments 400- 500µl Protein (c = 0.3- 0.6mM) were used. For 3D 
Experiments the same volume was used but concentrations between 0.5 and 0.6mM. 
In all NMR experiments 20mM Na-Phosphate buffer pH = 6, 20 mM NaCl was used. 
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2.4.2.3 Pulse Sequences 
Figure 20: Sequence of PFG- PEP- HSQC (Dorigoni 2006) 
 
The other pulse sequences were derived from the paper (Sattler Michael 1998).
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2.5 Materials 
2.5.1 Used Vectors 
 
pETM-13: 
 
 
 
pETtrx_1a: 
HAE1ct was cloned in there instead of GFP.  
 
 
 
 
 
 
 
  
56
 
2.5.2 Primers 
 
HCAIIF1 (forward) 
5'                                                                                      3' 
AATTGGTCTCCCATGTCCCATCACTGGGGGTAC 
 
HCAIIR2 (reverse) 
5'                                                                                           3' 
GGTACCGAGACCTTATTTGAAGGAGGCTTTGATTG 
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2.5.3 Cell strains 
 
Cell Strains Genotype Description 
DH5α  
supE44 ΔU169 deoR 
(f80lacZAM15)hsdR17 
recA1 endA1 gyrA96 thi-1 
relA1  
High copy plasmid cell line 
XL1-blue  recA1, lac-, endA1, gyrA96, 
thi, hsdR17 (rk-, mk+), 
supE44, relA1, λ-, [F', 
proAB, lacIqZ, ΔM15, Tn10 
(tetr) 
 
 
BL21 (DE3) F- ompT hsdSB (rb- mB-) 
gal dcm (DE3)  
The (DE3) cells carry a 
chromosomal copy of the 
T7 RNA polymerase gene 
under control of the lacUV5 
promoter. This strains are 
used for protein expression 
of pET vectors. 
Rosetta (DE3) F- ompT hsdSB (rb- mB-) 
gal dcm lacY1 (DE3) 
pRARE6 (CmR) 
 
This strain is derived from 
the Tuner cell and is used to 
enhance the expression of 
eukaryotic proteins that 
contain rare codons. This is 
accomplished by supply 
tRNAs for AGG, AGA, 
AUA, CUA, CCC, GGA 
codons on a compatible 
chloramphenicol-resistant 
plasmid.  
Rosetta (DE3) pLysS F- ompT hsdSB (rb- mB-) 
gal dcm lacY1 (DE3) 
Same as above but has an 
additional vector 
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pRARE6 pLysE (CmR) 
 
transformed that produce a 
larger amount of T7 
lysozyme than that of 
pLysS. In Rosetta (DE3) 
pLysE the rare tRNA genes 
are carried on the same 
plasmids that carry the T7 
lysozyme. 
C41 (DE3)  derived from BL21(DE3) 
It has at least one 
uncharacterized mutation 
which prevents cell death 
associated with expression 
of many toxic proteins.  
BL21* (DE3) F- ompT hsdSB (rB-mB-) gal 
dcm rne131 (DE3) 
The mutation in the rne 
gene which encodes for 
endonuclease RnaseE 
enhances mRNA stability.  
BL 21 (DE3) pLysS Genotype: 
F- ompT hsdSB (rb- mB-) 
gal dcm (DE3) pLysE 
(CmR) 
Same as above but has an 
additional vector 
transformed that produce a 
small amount of T7 
lysozyme that is used to 
suppress basal expression of 
T7 RNA polymerase prior 
to induction and thus 
reduces leaky expression.  
C41 (DE3) pROS  C41 (DE3) transformed 
with pROS (Plasmid coding 
for t- RNAs for rare 
codons).  
C43 (DE3)  Is derived for C41 (DE3). It 
can express a different set 
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of toxic proteins than 
C41(DE3)  
Tuner (DE3)  F- omT hsdSB  (rB-mB-) gal 
dcm lacY1 
The lac permease (lacY) 
mutation allows uniformally 
entry and IPTG- 
concentration dependent 
low level to high level 
expression. Low level 
expression can improve the 
solubility and activity of 
difficult target proteins.  
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2.5.3.1 Genetic Markers 
 
Table 2: Genetic Markers; Novagen  2004/ 2005 catalog 
 
 
  
61
2.5.4 Media 
 
1×LB 20g/l LB Broth (Sigma) 
2×LB 40g/l LB Broth (Sigma) 
Autoinduction Media 928ml ZY; 1ml 1000×metal mix; 50ml 20×NPS; 20ml 
50×5052  
1×M9 Minimal Media 6g Na2HPO4×2H2O+ 3g KH2PO4+ 0.5g NaCl+1g NH4Cl 
+1l water and then autoclaved; 10ml Trace elements; 0.3ml 
1M KCl; 1ml Biotin; 1ml Thiamin; 2ml 1M MgSO4; 3-4g 
Glucose; 
For N15 labelling 1g N15H4Cl was used. 
For double labelling (N15 and C13 labelling) 1g N15H4Cl 
and 3-4g C13 labelled Glucose was used. 
 
 
Solutions needed: 
 
ZY (1l):  
10g Tryptone; 5g Yeast Extract ad 1000 H20 and autoclave 
 
20×NPS (ll):  
66g (NH4)SO4; 136g KH2PO4; 142g Na2HPO4; 900ml H2O 
Add in sequence in beaker, stir until dissolved; pH should be ~6.75; than autoclave 
 
50×5052 (1l):  
250g Glycerol; 730ml H2O; 25g Glucose; 100g Lactose 
Add in sequence in a beaker, stir until dissolved, autoclave 
 
1000×metall mix: 
50ml 0.1M FeCl3×6 H2O dissolved in 0.1M HCl; 2ml 1M CaCl2; 1ml 1M MnCl2; 1ml 
ZnSO4; 1ml 0.2M CoCl2; 2ml 0.1M  CuCl2; 1ml 0.2M NiCl2; 2ml 0.1M Na2MoO4; 
2ml 0.1M Na2SeO3; 2ml 0.1M H3BO3 
Autoclave the Stock- solutions except FeCl3 
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2.5.5 Antibiotics 
Kanamycin 100mg/ml  
Carbencillin 100mg/ml  
Chloramphenicol 34mg/ml 
The antibiotics were diluted 1:1000. 
 
2.5.6 Agar and Pds 
Agar  4,5g Agar + 300ml LB autoclaved 
Kanamycin Pds 300ml Agar + 150µl Kanamycin (100mg/ml) 
Kanamycin/Chloramphenicol Pds 300ml Agar + 150µl Kanamycin (100mg/ml)+ 
300µl Chloramphenicol (34mg/ml) 
Carbencillin Pds 300ml Agar + 300µl Carbencillin (100mg/ml) 
Carbencillin/Chlorampenicol Pds  300ml Agar + 300µl Carbencillin (100mg/ml) 
+ 300ml Chloramphenicol (34mg/ml) 
Always let the agar cool down before adding the antibiotics. 
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2.5.7 Buffer list 
2.5.7.1 Cloning 
2.5.7.1.1 Agarose Gels 
50×TAE  121g Tris; 28ml Acetic acid; 50ml 0.5 M EDTA pH=8; add to 
500ml with dH2O 
 
2.5.7.1.2 Peparation of Competent Cells 
RF1 Buffer  12g RbCl; 9.9g MnCl×4H2O; 30ml 1M KOAc pH=7.5; 1.5g 
CaCl×2H2O; 150g Glycerol 
RF2 Buffer  20ml 0.5M MOPS pH=6.8; 1.2g RbCl; 1.5g CaCl2×2H2O; 150g 
Glycerol 
 
2.5.7.2 Purification 
2.5.7.2.1 Nickelcolumn 
 
Gravitiy column 
Lysis Buffer  100 mM MES pH=6; 150 mM NaCl; 10 mM Imidiazol; 2 
mM Mercaptoethanol 
Elution Buffer  100 mM MES pH=6; 150 mM NaCl; 400 mM Imidiazol; 2 
mM Mercaptoethanol 
Striping Buffer  20 mM Tris- HCl pH=7.6; 1.5 M NaCl; 50 mM EDTA 
 
His Trap FF 5ml 
Buffer A 20ml MES pH= 6; 20mM NaCl 
Buffer B Buffer A+ 500 mM Imidiazol 
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2.5.7.2.2 Ion exchanger 
 
Cation exchanger 
Buffer A  50 mM MES pH=6.2 
Buffer B 50 mM MES pH=6.2 ; 2M (NH4)2SO4  
 
 
Anion exchanger 
Buffer A  100 mM MES pH=6; 20mM NaCl; 2mM Mercaptoethanol 
Buffer A  100 mM MES pH=6 ; 2M NaCl ; 2mM Mercaptoethanol 
 
2.5.7.2.3 Hydophobic Interaction 
Buffer A  50 mM MES pH=6.2 
Buffer B 50 mM MES pH=6.2 ; 2M (NH4)2SO4  
 
2.5.7.2.4 Size Exclusion  
For unlabeled Proteins (for Crystallography) 
Gelfiltrationbuffer  20 mM MES pH=6; 20 mM NaCl  
 
For labeled Proteins (for NMR) 
Gelfiltrationbuffer  20 mM Natriumphospatbuffer  pH=6; 20 mM NaCl  
 
 
2.5.7.3 Analysis 
2.5.7.3.1 SDS- PAGE  
2× Loading Buffer  12.5ml 1 M Tris - HCl pH=6.8; 30ml glycerol; 2g 
SDS; 36g Urea; 6.6ml mercaptoethanol;  ~0.2% 
bromphenol blue 
10×Running Buffer 30.25g Tris base + 144.1g glycine + 10g SDS add 
H2O to 1l 
Coomassie Staining Solution  150ml methanol; 150ml H2O; 21ml Acetic acid; 9ml 
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1%Coomassie R250 in H2O : Methanol (1:1v/v) 
Coomassie Destaing Solution  200ml methanol; 70ml Acetic acid; 730ml H2O 
 
 
Casting gels  
Table 3: : Casting gels; (Russell 2001) 
 
 
  
66
2.5.7.3.2 Westernblot and Expression Screen 
10× Transfer Buffer  29g Glycin+58g Tris+ 3.7g SDS in 800ml 
H2O and 200ml methanol 
1× Transfer Buffer  80ml 10× Transfer Buffer+ 720ml H2O+ 
200ml methanol 
TBST  20 mM Tris pH=7 
1st Antibody- Solution Rabbit anti-his antibody in TBST; dilution 
1:2 000 
2nd Antibody- Solution Mouse - Alkaline- phosphatase conjugated 
anti- rabbit- antibody in TBST; dilution 1: 
3 000 
Colour- development buffer 100 mM Tris- HCl pH= 9.5; 100 mM 
NaCl; 5 mM MgCl 
Denaturating lysis Buffer  8M Urea; 20 mM Tris pH= 8 ; 100 mM 
NaCl  
BugBuster Protein Extraction Reagent Ordered from Novagen 
 
2.5.7.3.2 Expression and Purification of TEV Protease  
Lysis buffer (100ml) 20 mM Tris pH=8; 10 mM Imidiazol pH=8; 150mM 
NaCl; 2 mM Mercaptoethanol (always add fresh before 
use) 
Wash 1 = Lyis buffer 
Wash 2 20 mM Tris pH=8; 10 mM Imidiazol pH=8; 1M NaCl; 
2 mM Mercaptoethanol (always add fresh before use) 
Wash 3 20 mM Tris pH=8; 50 mM Imidiazol pH=8; 150 mM 
NaCl; 
2 mM Mercaptoethanol (always add fresh before use) 
Elution buffer  20 mM Tris pH=8; 330 mM Imidiazol pH=8; 150 mM 
NaCl; 2 mM Mercaptoethanol (always add fresh before 
use) 
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2.5.8 Markers 
 
   
A. O´Gene Ruler 1kbp DNA Ladder ready- to use (SM 1163); Fermentas   
B. PageRuler™ Unstained Protein Ladder (SM 0661); Fermentas 
C. PageRuler™ Prestained Protein Ladder (SM 0671); Fermentas 
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3 Results 
 
3.1 Cloning 
 
The idea was to clone a co- expression vector for HCAII and his- trx- HAE1ct. That 
would have the advantage that the complex can interact from the beginning and can 
be purified by his tag of his- trx- HAE1.   
 
The idea was to design forward and reverse primer which can be cut at the same time 
by BsaI and the result of cutting are two different overhangs. This prevents ligation 
into the wrong direction. The created overhangs are compatible for ligation into the 
NcoI and Acc65I cleaved pETM-13 vector (Figure 21 and 22).  
 
 
Figure 21: BsaI restriction sites 
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Figure 22: Ligation of BsaI restriction sites with NcoI / Acc65I cut pETM- 13 
 
The plan was to do the following steps: 
1. PCR of HCAII- template in pACA- vector with Primers containing BsaI 
cutting sites 
2. Cut the fragment with BsaI 
3. Digest of  pETM- 13 with Acc65I and NcoI 
4. Gelextraction bigger part of pETM-13 to remove the ABD- fragment 
5. Ligation of cut fragment into cut pETM- 13 
6. Transform into XL1 blue or DH5α 
7. Prepare preculture of one colony and do Miniprep 
8. Cut the vector with BlgII + Xho II  
9. Do gelextraction for fragment (which now also carries the T7-promotor) 
10. Digest pET-trx_1a HAE1ct with BamH1+ XhoI 
11. Ligation the fragment into the cut vector 
 
Steps 1-4 were performed but there were problems with ligation (Figure 21).  
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Figure 23: Ligation 
 1: Marker, 2: Fragment produced by PCR, 3: pETM- 13 cut with Acc65I and NcoI after gelextraction 
(really faint band), 4: Ligation of fragment into cut and gelextracted pETM-13 
 
It seems that BsaI did not cut the fragment properly at one site and therefore blunt end 
ligation of 2 fragments has occurred. This step was tried several times but it didn´t 
give colonies after transformation.This uncomplete cleavage can occur if there are not 
enough nucleotides up- and downstream of the cutting site so that the restriction 
enzyme cannot bind properly. 
 
Therefore the alternative way was to ligate the fragment blunt- end into the EcoRV 
restriction site of pETM-13. Inserted into this vector the fragment should be cut by 
BsaI. PCR of the Fragment with Pfu- Polymerase (no Poly-A-Tails at 5´) and digest 
of pETM-13 with EcoRV were performed. Then the fragment and the plasmid were 
ligated. 
 
Before transformation the ligation- mixtures were cut with EcoRV because of blunt 
end ligation a lot of vectors would just close again. If the fragment is inserted the 
cutting site, it will be split by its insertion. Vectors without the fragment inserted have 
an intact Eco RV restriction site. Therefore they will be linearized and are excluded 
from transformation. The transformation gave around 20 colonies on Kanamycin 
plates. To check if the fragment was inserted in the plasmid, Mini Prep and PCR were 
done. 
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Figure 24: PCR of Mini Prep 
1: Marker, 2: Miniprep, 3: PCR1 on Miniprep, 4: PCR2 on Mini Prep, 5: Mini Prep 
 
The fragment is inserted because the PCR has produced fragments with the right 
length (Figure 22). The next step was to digest the plasmid by BsaI.  
 
 
Figure 25: Plasmid of Mini Prep cut with BsaI 
1: Marker, 2- 6: Plasmid with inserted Fragment cut with BsaI 
 
By the digest of the plasmid no fragment with the right size appears (Figure 23). 
There is the possibility that the PCR- Products from Miniprep have risen from 
unspecific interaction of the primers with the vector. It is rather improbable that this 
gives fragments with the right size but a negative control was done. A PCR was done 
on the empty pETM- 13 vector. If it gives products the primers anneal unspecifically. 
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Figure 26: PCR of empty pETM- 13 
1: Marker, 2: PCR of Fragment with Pfu- Polymerase, 3: same, 4: PCR of pETM-13 without insert, 5: 
same 
 
The primers do not bind unspecific (Figure 24). Maybe BsaI did not work properly. 
In the meanwhile the proteins were expressed and purified with the already existing 
vectors.  
 
 
 
  
73
3.2 Expression and Purification of unlabeled proteins 
3.2.1 HCAII 
3.2.1.1 Expression 
 
HCAII was expressed with BL21. 1 l was enough to get a sufficient amount of 
protein. The addition of ZnSO4 to the media is essential for the correct folding of the 
protein. The expression of HCAII can be increased by lowering the temperature after 
induction with IPTG to 30°C and following expression over night.  
 
3.2.1.2 Purification 
 
For the first step of purification high pI (6.5) of HCAII is exploited by a SP Sepharose 
FF column (Figure 27). 
 
 
Figure 27: Chromatogramm of SPSepharoseFF HCAII 
Slot1: Pellet1; 2: Pellet2; 3: Supernatant1: 4: Supernatant2; 5-10: Fractions; 11: Marker 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
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An alternative and faster way is to use a gravity Nickelcolumn (Figure 28). HCAII 
was not expressed with a his - tag but it was empirically proved that it binds to Nickel. 
This can be explained by the 5 histidines which are N- terminal and very close to each 
other. 2ml Nickel- resin were used per liter expression. Normally still a lot of protein 
was in the load fraction after the first run. For this reason the procedure was done 
twice.The other possibility is to increase the bed volume to 4ml but then the flow 
velocity is nearly decreased to zero. For every run 6- 10 fractions were eluted. 
 
Figure 28: Fractions Nickel gravity column 
Left: 1: Marker; 1: Pellet 1; 3: Pellet 2; 4: Supernatant Flow through after second run; 5: Wash 
first run; 6: Wash second run; 7-13: Fractions first run  
Right: 1: Marker; 2-9: Fractions second run 
 
As second step a hydrophobic interaction column (Phenylsepharose) was performed 
(Figure 29). 
 
Figure 29: Chromatogram of Phenylsepharose FF – Column HCAII 
Gel: 1: Marker; 2-10: Fractions of Phenylsepharose FF- column 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
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Finally Size exclusion on Superdex 200 26/60 was done to get ride of the small 
shoulder visible in the chromatogram (Figure 30). 
 
       
Figure 30: Chromatogram size exclusion HCAII;  
Gel: 1: Marker; 2-4: Fractions Size Exclusion 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
 
Per 1l of expression 25- 39mg HCAII could be purified. 
 
3.2.2 His- trx- HAE1: 
 
Because of its size (4kDa) the peptide HAE1 was expressed in N- terminal fusion 
with his-tagged thioredoxin (14kDa). The his- trx part can later be cut of by TEV 
(Figure 31).  
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Figure 31: Picture of his- trx- HAE1 with internal TEV- cleavage site.  
 
3.2.2.1 Expression 
 
The protein was expressed in 1 l LB. In the beginning the strain BL21 pLys was used 
but due to expression - studies for the labeled form (See expression of labeled 
proteins; his- trx- HAE1) we decided to continue with C41 pROS. This change 
improved the expression by around 1/3. 
 
3.2.2.2 Purification 
 
The first step of purification was done with a Gravity- Nickelcolumn.  
Two runs were necessary because of the improved expression with C41 pROS.  
6- 12 Fractions were eluted (Figure 32).  
 
    
 
Figure 32: Fractions Nickel gravity column his- trx- HAE1ct  
Left: 1: Marker; 2: Pellet1; 3: Pellet2; 4: Supernatant Flow through after second run; 5: Wash first run; 
6: Wash second run; 7-14: Fractions first run; 15: Marker 
Right: 1: Marker; 2-10: Fractions second run; 11: Marker 
 
For the next step the protein was loaded on an Anionexchanger (Hi TrapQ FF 1ml). 
To avoid loss by overloading the fraction X1 of the 1st run was loaded again (Figure 
33and 34).  
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1st. run: 
 
 
Figure 33: Chromatogram of Hi Trap Q FF 1ml 1. run his- trx- HAE1ct  
Gel: 1: Marker; 2-10: Fractions first run 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
 
2nd run: 
 
Figure 34: Chromatogram of Hi Trap Q FF 1ml his- trx- HAE1ct 
Gel: 1: Marker; 2-8: Fractions 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
To get ride of the last impurities a gelfiltration on a Superdex 200 26/60 was run 
(Figure 35). 
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Figure 35: Chromatogram of Size Exclusion on Superdex 200 26/60  
Gel: 1: Marker; 2- 7: Fractions 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
In average 10- 20mg his-trx-HAE1 could be purified out of 1l.  
 
3.3 Expression and Purification of labelled proteins 
3.3.1 HCAII 
3.3.1.1 Expression 
 
A Pre-run in unlabeled M9- Minimal media showed that the expression is comparable 
to the expression in LB. Therefore no optimization was necessary.  
HCAII was expressed in the N15- and the N15 C13 labeled form. 
3.3.1.2 Purification  
The purification was done the same way as with the unlabeled protein and the final 
amount was also 20-25 mg.  
 
3.3.2 His- trx- HAE1 
3.3.2.1 Expression 
It was determined by that the expression of his- trx- HAE1 nearly goes to zero in M9- 
Minimalmedia. Even a screen for the optimal IPTG, Glucose- concentration or 
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Expression- temperature did not help. Therefore the expression in different cell lines 
was compared in an Expression – Screen.  
 
 
Figure 36: Dot blot of expression Screen of his- trx- HAE1 in different cell lines at 21°C and 37°C  
(Left spot stands for the soluble and the right for the total amount of protein) 
 
The dots show the soluble (left) and total (right) amount of protein expressed in the 
cell lines. It is clearly visible that the strain C41pRos at 37°C is expressing the highest 
fraction of soluble protein (Figure 36)and therefore it should be the bacterial strain of 
choice.  
This strain is normally used for toxic proteins. It is highly probable that the peptide 
HAE 1 alone is unfolded and therefore it might be encountered as toxic under high 
pressure like in Minimal- Media. 
 
Again a pre- run of expression in M9- Media was done and the change to the new 
strain led to a dramatically increase of expression (Figure 37). 
 
    
Figure 37:Expression in BL21 (left) and Expression in C41pRos (right) 
Left :1 and 3- 8: Fractions of Nickelcolumn  2: Marker; 9: Pellet; 10: Supernatant after Loading 11: 
Wash Fraction after loading  
Right 1: Marker 2-3:Pellet 1and 2; 4: Supernatant after Loading; 5: Wash Fraction after loading; 6- 12; 
Fractions of Nickelcolumn 
 
C41pRos was used to express his- trx- HAE1 in the N15 C13 labeled form and the 
expression of unlabeled his- trx - HAE1 was also continued with this strain.  
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3.3.2.2 Purification 
 
The same protocol was used as for unlabeled his- trx- HAE1ct. 
For the labeled form 10-15mg of protein were purified.  
 
3.4 TEV- cleavage and Complex Formation 
 
The complex should be formed in a buffer with low pH and ionic strength. It was also 
proved that the time course of the interaction is rather slow with a t1/2= 12h in a buffer 
pH = 7.5 containing 100mM NaCl. Lower pH and ionic strength will decrease the 
time required for saturation (Vince and Reithmeier 1998). 
 
To be sure that the interaction will reach saturation the complex was formed 24h on 
4°C though we have choosen a buffer with lower pH and ionic strength (See buffer 
list Gelfiltration- Buffer). Once locked the interaction should be strong even in more 
unfavourable conditions.  
 
The his- tag and the thioredoxin have to be removed from his- trx- HAE1 by TEV. 
This can be done before or after the formation of the complex. Both possibilities were 
tried.  
 
3.4.1 Complex Formation followed by TEV- cleavage: 
 
The complex was formed 1:1 on 4°C for 24h and then cleaved overnight by TEV on 
4°C. To separate the cleaved from the uncleaved complex it was loaded on a HisTrap 
HP 5ml column (Figure 38).  
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Figure 38: Chromatogramm of Complex on HisTrap HP 5ml after complex formation and TEV- 
cleavage 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
Two peaks are eluted with the increasing gradient of imidiazol. This was expected 
because HCAII should also bind to Nickel (see Purification of HCAII) but in a lower 
extent than the his- tag of his- trx- HAE1ct. Therefore the first peak should be contain 
the cleaved and the second the uncleaved complex.  
The fractions were put on a gel. This revealed that the cleaved complex contains 
components of 29kDa (HCAII) and 12kDa. But HAE1ct should have a size of 4kDa. 
Therefore the fractions of the first eluted peak were loaded on superdex 200 26/60 to 
get ride of possible contaminants (Figure 39).  
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Figure 39: Chromatogramm complex on Superdex 200 26/60 with Gel  
1: Marker; 2-7: Fractions 1- 6 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
It is visible on the chromatogram that there are no significant contaminations. On the 
SDS PAGE again a band with 29kDa (HCAII) and a band of approximately 12kDa 
were detected. Maybe the interaction with the Nickelcolumn was not sufficient to 
separate the fractions dependent on his- tag.  
 
To verify if the 12kDa band contains a his- tag and therefore could be a cleavage 
product of his- trx- HAE1ct, a Western Blot with primary anti- his antibodies was 
done (Figure 40).  
 
        
Figure 40: Parallelgel for Westenblot (left) and Western Blot (right) 
1: Negative control for his- tag; 2: Positive control; 3: his- trx- HAE1ct cut with TEV; 4 and 5: 
Concentrated fractions of gelfiltration 
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It seems as if it does not contain a his- tag. Therefore the origin of the 12kDa band is 
still unclear.  
Even more striking is the fact that the 4kDa HAE1ct peptide is not detectable in the 
fractions with should contain the cleaved complex.  
 
3.4.2 TEV- cleavage followed by complex formation 
 
A small volume (0.5-1ml) of concentrated his- trx- HAE1ct (12- 16mg/ml) in 
Gelfiltration-Buffer (See Buffer list) was cleaved for 2h on RT with TEV. More TEV 
was added and cleavage was continued over night on 4°C.  
To separate the cleaved from the uncleaved part a gravity Nickel-column with 1ml 
resin was used. The cleaved fractions will be in the flow through while the uncleaved 
his- tag containing fractions and TEV will bind to the resin.  
The sample was loaded and up to 4ml Gelfiltration- Buffer were used to wash out the 
nonbinding part. With Gelfiltration- Buffer + 400mM Imidiazol the Nickel- binding 
fractions were eluted.  
 
The Flow- trough fraction was freeze dried because HAE1ct (4kDa) is too small to 
concentrate it with a Centripore device. Therefore the volume should be kept is small 
as possible because the buffer components will also be concentrated by freeze drying.  
 
Aliquotes of the different steps were loaded on a 12% SDS Gel (Figure 41). 
 
 
Figure 41:  Cleavage of his- trx-HAE1ct and purification of HAE1ct 
 1: his- trx-HAE1ct; 2: his- trx- HAE1ct cleaved with TEV; 3: Flow through fraction on Nickelcolumn; 
4: Eluted fraction of Nickelcolumn 
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The flow through fraction contains a band at 10kDa. This is due to the low percentage 
of the gel. On a 18% SDS- PAGE the fraction runs at 4kDa (Data not shown) and 
therefore can be identified as HAE1ct region. The separation of cleaved and 
uncleaved parts seems to be sufficient. 
 
Finally the freeze dried fraction was diluted with water to the desired concentration. It 
has to be taken into account that the solution contains the amount of 6ml of 
Gelfiltration- Buffer. Therefore high volume of buffer before freeze drying can 
impede the complexing or even make it impossible.  
The complex with HCAII was formed on 4°C for 24h.  
 
3.5 Crosslinking of the Complex 
3.5.1 Crosslinking with BS2HG 
 
To identify the interaction site between HCAII and HAE1ct the complex had to be 
with BS2G and afterward analyzed by mass spectrometry(Rappsilber, Siniossoglou et 
al. 2000; Sinz, Kalkhof et al. 2005). The complex was formed for this purpose with 
different rations of HAE1ct (1-5parts). As a negative control HCAII was crosslinked.  
α- actinin was crosslinked to serve as a positive control because it is forming a 
homodimer and therefore the  probability that Lysins or the Amino-termini come 
close enough to be crosslinked is rather high. 
Aliquotes were taken and loaded on 10%Gels (Figure 42). 
 
 
Figure 42: Crosslinking with BS2G;  
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1: Complex without crosslinker; 2: Marker; 3: HCAII crosslinked; 4: Complex (1:1) crosslinked; 5: 
Complex (1:2) crosslinked; 6: Complex (1:3) crosslinked; 7: Complex (1:4) crosslinked; 8: Complex 
(1:5) crosslinked; 9: Positive control α- actinin; 10: Marker 
 
It is easy to see that the uncrosslinked complex (1) contains the peptide in an 
sufficient amount. As mentioned before it runs higher size than 4kDa on Gels lower 
then 18%. α- actinin was partially crosslinked by BS2G and therefore the reaction 
seems to work.  
Unfortunately the negative control of HCAII crosslinked (3) looks exactly the same 
like the aliquots taken from complexes crosslinked (4-8).  
All of these fractions show a smear from circa 27- 35kDa. HCAII is containing 24 
Lysins to which the crosslinker could bind without crosslinking and therefore produce 
this smear.  
It could be possible that the band of the crosslinked complex HCAII –HAE1ct is 
overlaid by this smear and therefore no difference to the negative control is 
detectable.  
 
This was tested by a series of RESOURCE Q runs.  
HCAII has an pI of 6.5 while the complex HCAII – HAE1ct is more acidic with a pI 
of 5,64. In pH = 6 HCAII carries positive charges. In contrast the complex is 
negatively loaded. That means that these fractions can be easily separated by an anion 
exchanger. The flow through will contain HCAII while the complex will bind to the 
column and will be eluted by salt.  
The RESOURCE Q column has lower capacity but higher resolution than HiTrap Q 
1ml column and was therefore chosen for this purpose. 
 
In the first two runs HCAII and Complex native were loaded (Figure 43). For both a 
peak after 5ml (1 column volume) was detectable. This was expected because the 
HCAII should be positive charged. HAE1ct should be separated from the complex by 
the positive groups in the column because its pH alone is 3.82 and should be eluted 
later. No peak peak is detected because HAE1ct only contains two aromates and 
therefore will not show a high peak of absorption in the chromatogram.  
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Figure 43: HCAII not crosslinked (left) and Complex not crosslinked (right) 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
The next two sample loaded were HCAII and Complex, both crosslinked with BS2G 
(Figure 42).  
Their chromatograms show a peak at 25ml at the beginning of the salt gradient. The 
crosslinker has masked some Lysins of the HCAII therefore it is not as positive 
charged as the native form. For successful crosslinking a second peak at a higher 
percentage of salt would be expected.  
The chromatograms show clearly that no crosslinking of the complex has taken place.  
 
 
Figure 44: HCAII crosslinked with BS2G (left) and Complex crosslinked with BS2G (right) 
(x- axis = volume in ml; y- axis= absorption at 280nm in mAu) 
 
The different fractions were also crosslinked with formaldehyde to compare the 
methods and the results.  
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3.5.2 Crosslinking with Formaldehyd 
 
The complex in ratio 1:2 (HCAII : HAE1ct) was crosslinked with 0.5-1% 
Formaldehyd. α- actinin was acting again as a positive control. Here 1% Formaldehyd 
was used. For the negative control HCAII was crosslinked with 2% Formaldehyd. The 
samples were run on a 10% SDS PAGE (Figure 45). 
 
 
Figure 45: Crosslinking with Formaldehyd 
Slot 1- 6: Complex crosslinked with 0.5%, 1%, 1.5%, 2% and 10% Formaldehyd; Slot 6: α- Actinin 
crosslinked with 1% Formaldehyd (positive control) 
 
The positive control is completely crosslinked while the negative control does not 
show any crosslinking. Also the complex does not show any crosslinking. 
This could be due to the high pH of the buffer which could destroy the complex which 
was formed in the Gelfiltration-buffer in high concentration. The complex should be 
rather stable when once locked on but the dilution in a buffer with pH = 8 might have 
destabilized it to a high extent.  
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3.6 Crystallography 
 
As mentioned before two orders of TEV- cleavage and complex formation were tried. 
Crystallization was tried with both forms.  
 
3.6.1 Crystallization of complex formed by complex generation 
followed by TEV- cleavage 
 
Different initial crystal screens of the complex were done with the crystallization 
nano-robot: 
- JCSG (Quiagen) 
- PACT ( Molecular Dimensions Limited) 
- HAMPTON Research Index Screen (HAMPTON) 
- HAMPTON Research Grid Screen (HAMPTON) 
 
They were kept at 22°C. After 24h crystal plates were found in conditions D5, D6, 
D7, D8, D10, D11, D12 and G11 of the Grid screen. The Index Screen gave also rise 
to hits in condition B8 after one day. 
 
By analysis of the crystallization condition three possible refinement strategies were 
designed: 
A. 0.1 M buffer (Tris, HEPES, Bicine) with pH from 7 to 9 containing 2.4 or 3.2 
M ammonium sulphate   
B. 0.1 M citric Acid pH 4 or 5 containing 3.2M ammonium sulphate 
C. 0.1 M HEPES pH= 7.5 containing 1.4 M Na citrate 
 
Three refinement Screens were done manually by hanging drop vapour diffusion set-
up in Nextal plates.  
1. 0.1 M Citric acid pH 4 up to 5 against 2.4- 3 M ammonium sulphate 
2. 0.1 M bicine buffer pH 8 – 9 against 2.4- 3M ammonium sulphate 
3. 0.8 – 1.8 M Na- citate against 0.1 M Buffer pH 5- 8 (MES and bicine) 
 
The whole second plate gave rise to crystals (Figure 46). In third plate crystals grew 
in the conditions marked with a cross (Table 4).  
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Table 4: Refinement screen 
 0.8M Na- Citrat 1M 1.2M 1.4M 1.6M 1.8M
pH= 5             
6           × 
7         × × 
8       × × × 
 
     
 
Figure 46: Crystals in 0.1M bicine pH = 8.6 2.6 M (NH4)SO2 (left) and 0.1M bicine pH=7 1.8 M 
Na- Citrate 
 
For citric acid with ammonium sulphate (Plate 1) the crystals could not be 
reproduced.  
 
Diffraction experiments: 
Diffraction data on the two crystal grown in conditions 0.1 M Bicine pH= 8.2; 2.4M 
ammonium sulphate and 0.1 M bicine pH = 8; 1.4 M Na- citrate were collected on our 
home facility (Table 5 and 6).  
 
Table 5: Data collection statistics of 0.1 M Bicine pH= 8.2; 2.4M ammonium sulphate 
Data collection  
Beamline                                                                                                        Bruker proteum X8 
Wavelength (Å)         1.54 
Space group                                                                            P21 
Unit cell parameters (Å)         
a   42 
b          41.3 
c          71.9 
Resolution range (Å)                                                                                          69.84 – 1.75 (1.85 – 
1.75) 
Observed reflections  118089 
Unique reflections   44371 
Rmerge      0.0211 (0.1914) 
< I >/< σI >      21.55 (5.1) 
Completeness (%)      98.9 (96.3) 
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Redundancy                                                                                                    4.67 (2.25) 
 
 
Table 6: Data collection statistics of 0.1 M bicine pH = 8; 1.4 M Na- citrate crystal 
Beamline                                                                                                        Bruker proteum X8 
Wavelength (Å)         1.54 
Space group                                                                            P21 
Unit cell parameters (Å)         
a   42 
b          41.3 
c          71.9 
Resolution range (Å)                                                                                          41.44 – 1.70 (1.79 – 
1.70) 
Observed reflections  122079 
Unique reflections   50620 
Rmerge      0.0271 (0.1626) 
< I >/< σI >      16.9 (4.38) 
Completeness (%)      99.8 (98.7) 
Redundancy                                                                                                    4.5 (2.63) 
 
 
Both were monoclinic and were members of the space group P21.The unit cell had in 
both chases a size of 70×41×41Å3.  
The phase problem was solved with MR using the structure of HCAII alone (pdb 
entry code 1ca2). 
Inspection of difference electron density maps showed no additional electron density 
for the presence of the bound peptide, indicating the crystals contained HCAII only. 
Analysis of crystal packing revealed that it will be difficult to soak crystals of this 
space group because the N- terminus which is supposed to interact with HAE1 C-
terminal region makes crystal contacts, and might therefore in this crystal lattice not 
be available for additional intermolecular interactions. 
 
3.6.2 Crystallization of complex formed by TEV- cleavage followed 
by complex formation  
 
12 - 19 mg /ml compex were used for crystallization set-ups.  
 
The following crystallization screens were set up with the nano-robot: 
 
- JCSG (Quiagen) 
- PACT (Molecular Dimensions Limited) 
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They were kept at 22°C. After 2 days in conditions 5,7,12, 15, 23, 24, 34, 49, 50, 52, 
57, 59, 60, 67, 68, 69, 70, 76, 78, 79 and 80 of JCSG- screen small crystals mixed 
with a lot of  precipitate were visible. In condition 71 (1 M Succinic acid pH= 7; 0.1 
M HEPES pH 7; 0.5% v/v Jeffamine ED- 2001 pH 7) really regular but very small 
pyramids were found.  
25% of the conditions that yielded positive hits contained malic acid or malonate. 
In the PACT screen only amourphous brownish precipitate and phase separation were 
found.  
 
Two methods for refinement were chosen: 
 
A. In Nextal plates for the hanging drop 1µl condition 59 was mixed with 1µl 
complex and different concentrations of NaCl  (0.1 – 1M) or different 
percentages of PEG 8000 (15- 30%) were put in the reservoir to push the drop 
in the region of crystal growth  
B. For refinement 50- 600 mM Na- Malonate pH 5.5 - 6.5 were used with 20% 
PEG 4000 because malonate and malic acid seem to stabilize the complex 
 
For method A the crystals could be reproduced and the best results were obtained with 
reservoir containing 0.5 M NaCl. They contained pyramids slightly bigger than those 
obtained from the initial screen (Figure 47) and in addition slightly irregular crystals 
with cubic morphology. 
         
Figure 47: Complex in E11 (JCSG- screen) over reservoir with 0.5 M NaCl  
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Micro-seeding was tried in hanging drops with 1µl condition 59 and 1µl complex over 
0.5M NaCl or 15- 30% PEG 8000 equilibrated over night. The seeding was 
successful.  
To control that the obtained crystals are not made of salt control drops with 1µl 
gelfilration – buffer and 1µl Condition 59 were set over a reservoir of 0.5 M NaCl. No 
crystals grew in two weeks.  
 
Refinement strategy B only gave precipitate and phase- separation. Therefore higher 
concentrations of Na malonate (2- 3 M) pH 6 without PEG were used. 
Spherulites were found (Figure 48).  
        
Figure 48: Complex in condition 2.8 M malonate pH = 6 
 
Crystals at Synchrotron Grenoble: 
Therefore some crystals of both types were sent to the European Synchrotron Facility 
in Grenoble because the crystals were too small to test them with the home facility.   
From diffraction experiments it became clear that all of them consisted of salt. 
 
3.6.3 Soaking 
 
As the co- crystallization did not work it was tried to soak HCAII crystals with HAE1 
C-terminal region. Crystals of HCAII were grown from condition 0.1 M tricine  pH 
7.5  2.8 M ammonium sulphate at 22°C and 14°C in 24 well plates. After one day a 
lot of small crystals were visible in all drops at 14°C. The crystals in the trays on 
22°C grew after one week but were single per drop and much bigger but they did not 
grow in all drops.  
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Crystallization experiments with 0.1 M Tris pH 8.5 2.4 M ammonium sulphate were 
also set up and put on 14°C. Again a lot of small crystals grew after one day in all 
drops.  
 
3.6.3.1 Soaking with HAE1 C-terminal region 
 
The small crystals obtained from Tris and Tricine – condition (14°C) were soaked 
with 2µl HAE1 (5 mg/ml) which corresponds to a molar ratio of 1:4. The crystals 
partly cracked and dissolved (Figure 49) but some of them seemed to be quite stable 
so that diffraction data was collected with our home X- ray facility (Table 7).  
 
 
            
Figure 49: Crystals in condition 0.1M Tris pH=8.5 2.4M ammonium sulphate before soaking 
(left) and after soaking (right) 
 
They were monoclinic and were members of the space group P21. The unit cell had a 
size of 70×41×41nm. The phase problem was again solved with Molecular 
replacement.  
 
Table 7 Data collection statistics of HAE1 C- terminal region soaked crystals 
Data collection  
Beamline                                                                                                        Bruker proteum X8 
Wavelength (Å)         1.54 
Space group                                                                            P21 
Unit cell parameters (Å)         
a   41.9 
b          41.4 
c          72.2 
Resolution range (Å)                                                                                          70 - 2.08 (2.18 - 2.08) 
Observed reflections  160896 
Unique reflections   27498 
Rmerge      0.0134 (0.0585) 
  
94
< I >/< σI >      36.97 (11.07) 
Completeness (%)      99.8 (99) 
Redundancy                                                                                                    10.97 (3.93) 
 
Unfortunately again no additional electron density was detected. That means HAE1 
C-terminal region composed of 33 amino acid residues is maybe too big to be soaked 
into the crystals.  
 
3.6.3.2 Soaking with LDADD 
 
There seems to be a consensus sequence LDADD for the interaction with HCAII 
(Vince, Carlsson et al. 2000) which is highly conserved. It can also be found in 
HAE1ct. Therefore this small peptide was ordered from Novagen because it should be 
easier to soak this small peptide in without breaking the crystals.  
A small amount of peptide powder was put into the drop with the HCAII crystal 
grown in 0.1M Tricine pH 7.5 2.8M (NH4)SO2 .  
 
 
Figure 50: HCAII Crystal grown in 0.1M Tricine pH= 7.5 2.8M (NH4) SO2 soaked with LDADD 
 
The crystal dissolved and cracked a bit on one side (Figure 50) but data was collected 
with our home facility (Table 8).  
 
Table 8 Data collection statistics of LDADD soaked crystalls 
Beamline                                                                                                        Bruker proteum X8 
Wavelength (Å)         1.54 
Space group                                                                            P21 
Unit cell parameters (Å)         
a   73.8 
b          41.2 
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c          83.8 
Resolution range (Å)                                                                                          69.7 – 1.43 (1.53 – 
1.43) 
Observed reflections  755065 
Unique reflections   143103 
Rmerge      0.0095 ( 0.1312) 
< I >/< σI >      27.45 (4.01) 
Completeness (%)      90.3 (47.3) 
Redundancy                                                                                                    8.56 (0.79) 
 
The crystals were monoclinic and were members of the space group P21. But 
according to other experiments (soaking with HAE1ct and crystallisation of complex 
formed by complex formation followed by TEV- cleavage) the dimensions of the unit 
cell have changed form 70×41×41nm to 70×41×80nm.  
This indicates that something has happened in the crystals due to soaking.  
The phases were solved by molecular replacement. However no additional electron 
density was found.  
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3.7 NMR Experiments  
3.7.1 Focus on HAE1ct  
3.7.1.1 3D Measurements of HAE1ct 
 
The nitrogen and hydrogen shifts of HAE1ct peptide N15 C13 labeled were detected in 
a 2D HSQC spectrum. 
To assign the amino acid residues of the peptide to the peaks in the HSQC spectrum 
different 3D measurements were performed(HNCA, HNCOCA, CBCACONH, 
HNCOCACB): 
The combination of those spectra makes it possible to identify the connectivity 
between amino acid residues (peaks) in the HSQC(2.4.2.2 Three dimensional NMR- 
experiments). 
As an example the HNCOCA and HNCA spectra of residue 26- 28 are shown (Figure 
51).  
 
 
Figure 51: Assignment HAE1ct; HNCOCA (left) and HNCA (right) of residue 26- 28 
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The HNCOCA spectrum shows in the C- dimension of the HSQC spectrum the cα - 
peaks of residue i-1 while the HNCA spectrum shows both residue i-1 and residue i. 
The same can be done with HNCACB and CBCACONH spectra which deliver 
important additional information because the chemical shift of cβ is very dependent on 
the amino acid residue. 
 
Nearly the whole primary sequence was assigned to peaks in the HSQC spectrum 
(Figure 52). But still the identity of some peaks stays unclear. A? and D? show cα- 
shifts of alanine and aspartate but they could not be assigned to the primary sequence 
with unique idenity. 
The peak assigned with Dar? n-h has the shifts of an aspartate whose precursor has a 
cα shift of an aromatic residue (58ppm). This would match with residue 22 or 31 but 
could not be assigned with certainty.  
Also for residue 18 two possibilities are existing. Therefore one residue is named 18 
and one with K18_2.  
E24 and E25 could not be distinguished from each other because they have both a 
glutamate as residue i-1. 
 
 
Figure 52: Assigned residues of HAE1 C- terminal (blue frame) 
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Figure 53: HSQC spectrum of HAE1ct native (below) 
 
For residue yaline 37 two peaks were assigned because proline 36 can exist in the cis 
or trans form which is changing the environment of residue 37 (Figure 53). For prolin 
36 no peak was detected because prolines are not visible in HSQC spectras. 
 
3.7.1.2 Titration of labeled HAE1ct with HCAII 
 
To map the interaction site C13 and N15 labeled HAE1ct (only N15 labeled would be 
necessary) and unlabeled HCAII were mixed in the following ratios (HCAII: 
HAE1ct): 
2:1   1:1   1:2   1:3 
The complex was each time incubated 24h on 4°C and HSQC- spectra were recorded 
respectively.  
 
The spectra were aligned to each other by residue 14. To identify the most shifted 
residues the concept of the total shift was calculated, using the differences between 
spectra (Figure 54).  
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Figure 54: Diagram of amino acid residues of HAE1ct peptide and their total shift 
 
Clearly visible three residues E8, L12 and E25 (or E24 because this residues could not 
be distinguished) seem to be extremely important for the interaction with HCAII. 
Therefore, a closer look was taken at these residues.  
 
3.7.1.3 Following the saturation of HAE1ct with HCAII by residues E8, L12 and 
E25 
 
Following E8, L12 and E25 during the respective titration experiments it is easy to 
see that these residues were extremely shifted downfield by the addition of HCAII up 
to a ratio of 1:1 (Figure 55).  
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Figure 55: Overlay of different HSQC- Spectra of HAE1C- terminal 
HAE1ct without HCAII (blue), HCAII and HAE1ct in ratio 2:1 (yellow); ratio 1:1 (green) 
 
If more peptide is added two different patterns evolve (Figure 56): beside the shifted 
peaks for E8, L12 and E25, also the native shifts of HAE1ct can be detected. Results 
indicate that the complex HCAII - HAE1ct is already saturated which ratio 1:1, 
meaning that the affinity constant is very high. Furthermore, results prove that the 
underlying interaction dynamics are slow with respect to the chemical shift time scale.  
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Figure 56: Overlay of different HSQC- Spectra: HAE1ct without HCAII (blue), HCAII and 
HAE1ct in  ratio 1:2 (maroon); ratio 1:3 (turqouise)  
 
Slow exchanges (>µs – ms) normally show this separated patterns. One reason for this 
slow exchange could be that HCAII can only interact either with the cis- or the trans- 
proline form of HAE1ct. Residue V37 shows a peak for the trans or cis form of its 
preceding proline residue without HCAII.  
 
 
Figure 57: Detail of overlaid HSQC Spectra: Residue V37 of HAE1 without HCAII (blue); in 
ratio (HCAII: HAE1ct ) 2:1 (green); 1:1 (yellow); 1:2 (brown); 1:3 ( turquoise)  
 
In the left overlaid spectrum (native; 2:1; 1:1) it is visible that peak 37_2n-h 
disappears when the binding is saturated (left) (Figure 57). This means that the 
peptide only binds with proline either the cis- or the trans- form. By the addition of 
more peptide again the peak reappears which shows that the preceding proline of V37 
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exists again in the cis- and trans- form because the binding is oversaturated by the 
abundant peptide.  
 
3.7.2 Focus on HCAII 
3.7.2.1 3D measurements of HCAII 
 
3D measurements were done with double labeled HCAII. Because of problems with 
the spectrometer only cα- shifts were measured in HNCA and HNCOCA spectra. 
Without the more characteristic cβ- shifts the assignment gets much more difficult. 
Moreover HCAII is consists of 260 amino acids therefore many combinations have to 
be tested during assignment which is rather time consuming.  Therefore we were 
looking for alternative ways to full manual assignment. Nevertheless we continued 
with titration (Figure 58).  
 
 
Figure 58: HSQC – Spectrum of HCAII  
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3.7.2.2 Titration of labeled HCAII with his- trx- HAE1ct 
 
N 15 labeled HCAII was mixed in different ratios with his- trx- HAE1ct and HSQC – 
spectra were measured. HAE1ct with tag was used because the measurements were 
made before we figured out the right order of tag- cleavage and complexing. As 
negative control his- trx : HCAII in ratio 2:1 was used. (Data not shown) 
The following ratios (his-trx- HAE1ct: HCAII) were used: 
3:1   2:1   1:1   1:2    
The complex was formed 24h on 4°C.  
 
 
Figure 59: Detail in overlay of HCAII spectra; HCAII native (yellow), his-trx- HAE1ct : HCAII 
in ratio 2:1 (turquoise), 1:1 (blue), 1:2 (green) and 1:3 (magenta) ; Residue 9 (left) and Residue 202 
(right)  
 
It is easy to see that the peaks were shifting most at ratios 3:1 and 2:1 (HAE1ct: 
HCAII) (Figure 59). At the other ratios the peaks move back to the native state. That 
is a contradiction to the results we got from the titration of labeled HAE1ct with 
HCAII. Here the saturation of the binding was reached at the ratio of 1:2 (HAE1ct: 
HCAII). That means that in titrations of labeled HCAII with his- trx- HAE1ct much 
more peptide is needed to get sufficient interaction. This aberration could be due to 
the fused his- trx- tag on HAE1ct. It could make the peptide more bulky and therefore 
change the binding behaviour. Results indicate that the affinity constante increases 
due to the his-trx- tag. And therefore the dynamic seems to change from slow to fast 
exchange. For this reason higher ratios of peptide with fused tag are needed to show 
interaction.  
The spectra were assigned with working numbers and the total shift was calculated by 
the difference of native HCAII to his- trx- HAE1ct: HCAII in ratio 3:1. 
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Figure 60: Diagram of HCAII residiues (working numbers) and their total shift 
 
Only a few peaks were highly shifted (Figure 60). But without an assignment we were 
not able to identify them. We focused on searching for the assignment of the shifted 
peaks. Different ways were tried.  
 
3.7.2.3 Assignment by Homology 
 
HCAII has 60% sequence homology to human carbonic anhydrase I (Liljas, Kannan 
et al. 1972). 
This isoform is already assigned and this information can be found in the Biological 
Magnetic Resonance Data Bank (BMRB) on internet.  
Therefore artificial peaks in HSQC spectrum based on the HCAI assignment were 
created and overlaid with the HCAII HSQC spectrum (Figure 61).  
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Figure 61: Detail spectrum of artificial HCAI peaks overlaid on unassigned HSQC spectrum 
 
But the homology of the isoforms is not big enough to use it as a help for assignment. 
Only some peaks showed a correlation in the spectra.  
 
3.7.2.4 Partial assignment of the shifted peaks 
 
The idea was that it is rather probable that shifted peaks have neighbors in primary 
sequence which are also shifted because they are also near the peptide binding site. 
That means that it should be possible to correlate at least some of the shifted peaks to 
each other by their cα- shifts. Therefore the strategy was to connect shifted peaks by 
their cα- shifts and to identify patches of interaction. This reduces the possibilities for 
assignment dramatically. 
To do this some borders had to be established to judge, which shifted peaks would be 
in the “pool” and how they were connected. The total shift had to be > 0.2ppm and for  
connectivity the difference of the cα- shifts had to be ≤ 0.3ppm. Based on these 
borders a list of residues i and their possible preceding residue i-1 was made (Table 
9). 
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Table 9: Possible correlation of residues (in working numbers) 
 
 
The cα- shifts (characteristic for an specific aa or a group of them) of these neighbors 
were crosschecked with the primary sequence to find matching residues compatible 
with the shifts. Some residues could be assigned with high certainty. If for residues 
with more uncharacteristic cα- shifts two or more possibilities were detected, the 
closest one (in 3D structure) to residues assigned with high certainty, was choosen. 
By doing so ~ 50% of those peaks could be assigned. Three peaks with working 
number 100, 125 and 202 had such characteristic cα- shifts that this was enough to 
identify them in the primary sequence of HCAII (Figure 62 and 63). 
 
Figure 62: Correlations by partial assignment of working numbers (blue) and amino acids 
(orange) 
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Figure 63: Primary Sequence of HCAII with residues mapped to binding site (blue squares) 
by partial assignment  
 
With this information the binding site of his- trx- HAE1ct on HCAII could be marked 
with pymol (Figure 64 and 65).  
 
 
Figure 64: HCAII (green) with marked Bindingsite (Magenta) and entry to active site front view 
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Figure 65: HCAII (green) with marked Bindingsite (magenta) side view (left) and bacl view 
(right). 
 
The Binding site is situated near the entry to the active site of HCAII. The patch of 
shifted peaks which is separated from the binding site seems to be an unspecific 
interaction of his- trx- tag with HCAII.  
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4 Discussion 
 
Due to problems cloning a co- expression vector, HCAII and his- trx- HAE1 C-
terminal region were expressed separately in BL21 pLys strain. The expression and 
purification yielded sufficient amounts of unlabeled proteins.  
The requirement for NMR experiments was to express the binding partners also in the 
labeled form by growing cells in M9 minimal media. The expression of HCAII was 
comparable to that in LB but not for the the fusion- protein his-trx- HAE1 C-terminal 
region. Eventually an expression screen, in which 7 bacterials strains were tested, 
revealed strain C41 pROS gave expression levels necessary to get reasonable amounts 
of protein. This strain is normally used for toxic proteins. The HAE1 C-terminal 
region part of the protein is believed to be unfolded unless bound to HCAII. Therefore 
under higher pressure like in minimal media the fusion protein could be encountered 
as toxic. The switch to expression in C41 pROS increased also the protein production 
in LB by around 20%.  
 
Previous studies discovered that complex formation is impeded in buffer with high pH 
and high ionic strength (Vince and Reithmeier 1998). We therefore choose 20 mM 
MES buffer at pH 6, 20 mM NaCl for this task. TEV- cleavage of fusion protein his- 
trx- HAE1 C-terminal region (18 kDa) can be performed before or after complex 
formation. Both strategies were tried:  
i) Complex formation followed by TEV- cleavage produced bands at size of HCAII 
(29 kDa) and 12 kDa on SDS- PAGE while no band for HAE1 C-terminal region 
(4kDa) was detected. For a clear identification of the unknown 12 kDa band and its 
origin mass spectroscopy should be performed.  
ii) TEV- cleavage followed by complex formation - bands with size of HCAII (29 
kDa) and HAE1ct (4 kDa) were detected on the SDS – PAGE. This strategy was 
therefore used to prepare the samples for NMR experiments while in the initial stages 
also samples derived from strategy (i) were used for co- crystallisation studies.  
 
As crystals obtained from co- crystallization studies were identified to be salt or 
HCAII alone, soak of HCAII- crystals with HAE1 C-terminal region or with the 
consensus sequence LDADD peptide were performed. All used crystals were 
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belonged to the P 21 space group with of the unit cell dimensions of 41×41×70 Å3, in 
which the crystal contacts are formed by the N- terminal portion of the enzyme. 
During soaking experiments with the HAE1 C-terminal region and the consensus 
sequence, the crystals partly dissolved, but nevertheless preserved sufficient 
diffraction capacity to give data to 2 Å resolution. The phase problem was solved by 
molecular replacement. Crystals soaked with HAE1 C-terminal region retained their 
unit cell dimensions upon soaking, but did not show additional electron density 
indicative of the presence of bound peptide.  
Soaking of crystals with the consensus sequence LDADD gave the same results. No 
additional electron density was detected for the bound peptide, but the unit cell 
dimensions changed to 40 ×80× 70 Å3. This could be due to a pH change induced by 
the high amount of LDADD containing amino residues with acidic character. 
 
The unsuccessful soaking experiments with both peptides can be mostly attributed to 
the fact that the N-terminal region of HCAII is involved in the crystal contacts and 
therefore inaccessible for binding to the peptide. Moreover, high ionic strength (2.8 M 
ammonium sulfate) and slightly basic (pH 7.5) conditions from which the crystals 
used for soaking experiments were grown, were not appropriate for the complex 
formation. Moreover, the soaked peptide, in particular HAE1 C-terminal region 
might, destroy the crystal contacts and/or is too big and bulky to be soaked in this 
crystal lattice. It is also possible that the initial unfolded peptide folds upon interaction 
and is therefore destroying the crystal lattice. 
Additionally, the consensus sequence peptide might not be sufficiently long to bind 
HCAII specifically. Binding studies of designed peptides would be necessary to 
address this question. 
 
NMR interaction studies are based on shifts in HSQC- spectra were performed in 
parallel. The spectrum of a protein alone is collected and referenced to the spectrum 
of the same protein in interaction with a binding partner. Changes in the spectrum 
(up- or downfield shifts) are due to this interaction, meaning that the change of the 
environment of amino acid residues due to proximity of the peptide or the protein is 
affects their shielding in the magnetic field.  
The shifted peaks can be assigned to amino acids involved in the interaction by 3D –
NMR experiments. This was performed for labeled HAE1 C-terminal region in 
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interaction with HCAII. It was discovered that additional to L886 which was already 
known to play an important role in this interaction (Vince, Carlsson et al. 2000), also 
E882 and E899 are involved and are even more essential for the binding reflected in 
their values for the total shift (Figure 54). 
 
The motif of leucine followed by a strech of four amino acid residues containing at 
least two acidic residues like D or E can be found in the sequence of different HCO3- 
transporters. It is rather striking that nearly all of them have glutamate in position 
leucine-4 and a glutamate or asparte in position leucine +13 (Figure 66). The E+4 is 
also found in the C- terminal part of aquaporine 1 (AQP 1). This reflects the universal 
importance of those residues for the interaction with HCAII. 
The only exceptions to this observation is AE3 and pendrin (a iodide/ chloride 
transporter in thyroid and kidney) indicating that these transporters have other or 
additional interaction motifs or have a weaker binding constant to HCAII. 
In agreement with this supposition, the transport capacity of AE3 does not enhance 
dramatically by the interaction with HCAII compared to AE1 and AE2 (Sterling, 
Reithmeier et al. 2001). The transporter DRA does not carry any consensus motif. But 
it is likely that a longer stretch of the C- terminus is exposed to the cytosol maybe 
including such a motif (Pushkin, Abuladze et al. 2004). Therefore it is not sure if this 
transporter also used a hydrophobic- acidic motif for the interaction with HCAII.  
 
 
Figure 66: Primary C- terminal sequence of different HCO3- transporters; (h= human; r= 
rabbit); (Pushkin, Abuladze et al. 2004) 
 
However, for the amino acid residues following leucine 886 in the consensus 
sequence L886DADD, no significant shifts in the HSQC- spectrum reflect their 
importance for the interaction were detected. These amino acids might not be 
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essential for the interaction but help to position leucine residue in the binding site. 
Namely, the acidic amino acids could increase the pressure on leucine to bind to a 
hydrophobic patch.   
 
The same studies were performed for labeled HCAII in interaction with his- trx- 
HAE1 C- terminal region. Characteristic shifts were observed indicating an 
interaction. The difficulties of correlating the shifted peaks to amino acids in the 
primary sequence rise with the size of a protein. Therefore a different strategy for 
HCAII was used. By partial assignment approximately 50% of the shifted peaks could 
be assigned. With the program Pymol the binding site on the 3D structure of HCAII 
was visualized. The peptide binds near the entry to the active site (Figure 64 and 65). 
 
Based on the value of total shift a row of importance for the interaction can be done 
for clearly shifted amino acids with a shift ≥ 0.47 ppm: 
 
 
Figure 67: Residues with total shift ≥ 0.47 ppm 
 
According to the value of the shift the residues 9 and 10 (Lysine- Histidine) as well as 
the stretch of the residues 4- 7 (histidine-tryptophan-glycine-tyrosine) seems to be 
essential for interaction. In previous studies the mutation of K9 and H10 did not go 
hand in hand with a significant decrease of binding to HCAII (Vince, Carlsson et al. 
2000). However the binding site could consist of different binding motifs and 
therefore the mutation of one is not interfering dramatically with the binding.  
 
It was surprising that not only residues in the N- terminal helical region are involved 
in the binding: given its significant shifts upon interaction N62 residue seems to have 
a key role in the interaction as well. 
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Figure 68: Front view HCAII with binding site (left) and side view (right) ; hydrophobic amino 
acids (cyan); amino acids with polar side chains (magenta); unspecific interaction site of his- trx – 
tag (blue) 
 
The residues K9- H10, N62 or K133 could be involved in electrostatic interactions 
with glutamate residues in HAE1 C-terminal region. Due to the higher intensity of the 
shifts (≥ 0.47 ppm), induced by binding of HAE1 C-terminal region, it is more likely 
that K9- H10 and N202 are stabilizing E822 and E899.  
The location of the unspecific binding of the his- trx- tag suggest an interaction of  
K9-H10 with E822 of HE1, while N202 interacts with E899. The distances would 
allow this interaction if the peptide folds into an α- helix.  
 
Future studies should be based on the analysis of mutations in HAE1 C-terminal 
region and HCAII. The mutation of E882 and E899 in HAE1 C-terminal region 
should decrease or lead to a complete loss of binding to HCAII. Also the role of N62 
and K9- H10 should be investigated.  
Moreover the secondary structure of the bound HAE1 C- terminal region should be 
determined by comparison of the Cα shift of the unbound and bound state. An α-
helical conformation would be reflected in a significant upfield shift in comparison 
with the unbound state, which was reported to be unfolded (Vince, Carlsson et al. 
2000) .   
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